Shares of Applied Optoelectronics (NASDAQ:AAOI) are up 20% in midday trading to around $190, snapping back hard from a Friday close of $158.41. The single-session pop lifts the stock’s year-to-date (YTD) 2026 gain to an impressive 439%.
Meanwhile, Lumentum (NASDAQ:LITE | LITE Price Prediction) stock is up 7% to $914 and Coherent (NYSE:COHR) stock is roughly flat near $363. All three optics names are riding the AI datacenter infrastructure wave, yet AAOI stock has been the clear runaway in 2026.
Today’s tailwind is NVIDIA‘s (NASDAQ:NVDA) Computex 2026, which reinforces the picks-and-shovels case for high-speed transceivers. The group is also rebounding from a rough prior week, when AAOI stock fell 13% and LITE stock dropped 10%.
AAOI Leads YTD, but Size Cuts Both Ways Applied Optoelectronics is the YTD champion at +439%, but its market cap near $15.1B gives AAOI stock more torque in both directions than its larger peers. Last week’s selloff and today’s snapback show how quickly that volatility can cut in both directions.
The fundamental story remains the 800G ramp. Applied Optoelectronics reported Q1 2026 revenue of $151.14 million, up 51% YoY, with datacenter revenue more than doubling to $81.4 million. CEO Thompson Lin stated that the company “completed our first volume shipment of our 800G products to one of our large hyperscale customers in Q1.”
The honest caveat: insider selling has been heavy. On May 19, multiple Applied Optoelectronics executives, including the CEO and CFO, sold large blocks at $173.26 and $190.36. That’s profit-taking during a historic rally, and it’s a potential signal that’s worth noting.
Lumentum’s 1-Year Wrinkle Here’s the comparison nuance. Lumentum stock has actually outperformed AAOI on a one-year basis, with LITE stock up 1,155% versus AAOI stock’s 1,118%. In other words, the YTD lens isn’t the only one investors should use.
Lumentum’s fiscal Q2 2026 revenue hit $665.5 million, up 66% YoY, with non-GAAP operating margin expanding 1,730 basis points. CEO Michael Hurlston flagged optical circuit switch backlog above $400 million and a multi-hundred-million-dollar co-packaged optics order deliverable in first-half calendar 2027.
However, some Lumentum insiders have been selling. Hurlston disposed of 5,438 shares on May 15 at $970.70, part of a broader executive-selling cluster across mid-May.
Coherent’s Steadier Climb Coherent is the steadiest of the three. Q3 FY2026 revenue hit $1.81 billion (+21% YoY), with datacenter and communications now 75% of the revenue mix. Coherent stock is roughly flat today after a strong run that included joining the S&P 500.
CEO Jim Anderson highlighted the deepening NVIDIA partnership and NVIDIA’s $2 billion investment in Coherent. Anderson asserted, “As AI datacenter infrastructure continues to scale, we are rapidly expanding capacity to meet demand.” COHR’s +94% YTD ranks third in this group but reflects a larger, more diversified base.
What to Watch The broader optics thesis is straightforward. Hyperscaler capex from Meta Platforms (NASDAQ:META) and other mega-caps is fueling demand for 400G, 800G, and 1.6T transceivers, and these three names are direct beneficiaries.
The risks are real, however. All three optics stocks trade as extended winners with premium valuations after extraordinary runs, and Applied Optoelectronics carries more execution risk and lumpier revenue than its peers. Furthermore, insider selling across all three names during the rally is a flag prudent investors should weigh.
Watch for whether AAOI stock holds today’s gains into the close, and check the next round of hyperscaler capex commentary for any shift in the demand picture. The 800G and 1.6T transceiver ramp updates from Applied Optoelectronics, Lumentum, and Coherent could shape the next leg of this trade.
The massive semiconductor rally is entering its third month, and it seems anything connected to semiconductors and data centers is going parabolic.
While watching stocks go straight up is exciting, rallies like this can't last forever, and eventually the true winners will be separated from those that just rode the market's coattails. Figuring which stock is which is crucial, which is why we've gone over the semiconductor industry with a fine-toothed comb.
Here are the five rallying chip stocks with the fundamentals to keep rallying.
Micron TechnologyThe stock responded with a 20% gain in a single day, driving the company's market cap above $1 trillion for the first time ever. Micron is one of three firms capable of producing large-scale quantities of high-bandwidth memory (HBM), along with Samsung and SK Hynix.
Recent earnings have backed up the bullish new target: the company grew revenue nearly 200% year-over-year (YoY) in Q2 2026 with record gross margins over 75%, and its backlog is filled through 2027. But despite its recent performance, MU still trades at just 9 times forward earnings.
MU shares had strong upward momentum before the UBS price hike, but the new target has sent the stock into a new stratosphere. However, despite the parabolic gains, the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) indicators don't show an overbought stock.
Wolfspeed Inc.WOLF shares have spent the last few weeks consolidating following the post-earnings pop, and actually pulled backed 20% last week. But this is likely a healthy correction after the stock rose well above trend and pushed the RSI into overbought territory. The uptrend remains strong with the 50-day moving average above the 200-day moving average, and the RSI is no longer overbought.
Marvell Technology Inc.Tiny fiber-optic networking company Applied Optoelectronics (NASDAQ:AAOI) has been one of 2026's big winners, soaring more than 350% YTD and boosting its market cap over $12 billion.
The company posted a larger-than-expected loss in its Q1 2026 report last month, but also recorded record revenue of over $150 million, its fourth straight quarter of positive revenue growth (and third of at least 10% sequential growth). Management expects another big revenue gain in Q2, guiding a range of $180 to $198 million.
Right now, AAOI shares could be offering a rare chance to buy at a discount. The stock has pulled back to the 50-day moving average and trades around $160, which is nearly 30% below the $220 price target Rosenblatt set following the Q1 earnings report. The RSI has also pulled back to its lowest point since April, which previously served as an excellent entry point.
Analog Devices Inc.Analog Devices (NASDAQ:ADI) might be the safest investment among the five companies listed here, thanks to its dual-pronged revenue stream.
Fiscal Q2 2026 was one of the best in the company's history, thanks to record sales of $3.62 billion and rapidly accelerating growth in two segments. The Communications segment, which supplies integrated circuits to data centers, grew 63% YoY, and the Industrial segment rebounded sharply, growing 38% YoY.
The Industrial rebound gives Analog Devices a separate growth engine should data center capex slow, and management also raised its dividend for the 22nd consecutive year.
ADI shares are "only" up 50% YTD, but there could be plenty of upside ahead as the stock catches up to some of its parabolic peers. ADI trades at 33 times forward earnings, which is below the industry average of 37, and now the stock has technical momentum with the RSI sticking above the bullish threshold of 50.
Market News and Data brought to you by Benzinga APIs
Applied Optoelectronics is experiencing hypergrowth, driven by surging demand for 800G/1.6T optical transceivers and aggressive capacity expansion. AAOI raised full-year revenue guidance to $1.1B, with management projecting sequential quarterly growth and a potential $6B annualized run rate by mid-2027. Despite margin compression and significant dilution, AAOI's valuation remains attractive at under 10x NTM sales for a company targeting 120% CAGR through FY28.
The optics complex is rallying together at midday Tuesday, and the leadership has flipped from yesterday. Coherent‘s (NYSE:COHR | COHR Price Prediction) stock is up 16% to $422, leading the group after lagging into Monday’s close.
Lumentum‘s (NASDAQ:LITE) stock is climbing 13% to $1,024, crossing the $1,000 psychological level. Applied Optoelectronics (NASDAQ:AAOI) stock is adding 8% to $201, extending its standout 2026 run.
The move is broader than any single headline. After several choppy weeks, the optics complex spanning Coherent, Lumentum, and Applied Optoelectronics is being repriced together.
Coherent: Laggard Turns Leader Coherent’s stock was the laggard among the three into Tuesday, down 4% over the prior week. Today’s jump suggests rotation into the broader optics complex rather than narrow momentum chasing.
The fundamentals support the move. In fiscal Q3 2026, Coherent posted revenue of $1.805 billion, up 21% year over year (YoY), with its Datacenter and Communications segment growing 41% to $1.361 billion, now 75% of total revenue. CEO Jim Anderson cited “exceptionally strong demand across our datacenter and communications businesses.”
NVIDIA‘s (NASDAQ:NVDA) $2 billion investment in Coherent, deepening their laser and optical networking partnership, remains a structural tailwind. The valuation isn’t cheap, with COHR stock trading at a forward P/E ratio of 49x.
Lumentum Crosses $1,000 Lumentum stock crossing $1,000 carries weight beyond the round number. LITE is a larger-cap, institutionally held name, so the price level matters for index and ETF flows.
The setup is fundamentally strong. The company’s fiscal Q2 2026 revenue came in at $665.5 million, up 66% YoY, and Lumentum guided fiscal Q3 2026 revenue to $780 million to $830 million, more than 85% YoY growth. Lumentum also disclosed an optical circuit switch backlog of more than $400 million and an incremental co-packaged optics order for first-half calendar 2027.
CEO Michael Hurlston described Lumentum as “mission-critical to the world’s AI leaders.” Analysts carry an average price target of $1,105 on LITE stock.
Applied Optoelectronics Extends Its 2026 Lead Applied Optoelectronics is the smallest-cap of the trio but the biggest 2026 percentage gainer. Today’s 8% session adds to a year-to-date (YTD) gain of 433% into Monday’s close.
Applied Optoelectronics’ Q1 2026 revenue rose 51% YoY to $151.14 million, with the datacenter segment more than doubling to $81.4 million on 800G transceiver demand. CEO Thompson Lin guided Q2 2026 revenue to $180 million to $198 million and emphasized “significantly larger growth expected starting in Q3 as additional capacity comes online.”
AAOI stock carries more execution risk than peers, with a beta of 3.76 and ongoing operating losses despite the revenue ramp. Investors should weigh the upside against this elevated volatility profile.
The Broader AI Optics Thesis and the Risks The unifying driver is hyperscaler capex flowing into 400G, 800G, and 1.6T optical transceivers connecting GPUs, racks, and entire datacenters. However, these optics stocks are extended winners.
Coherent stock is up 449% over one year, Lumentum stock 1,255%, and AAOI stock 1,219%. Premium valuations and customer concentration with a handful of hyperscalers make this a volatile group, as last week’s broad pullback demonstrated.
Prudent investors can size their positions accordingly, treating today’s broadening rally as confirmation of an established trend rather than a fresh entry signal. Investors can watch for hyperscaler capex commentary, 800G and 1.6T transceiver ramp updates, along with the next earnings prints from each name.
I initiate coverage of Applied Optoelectronics with a Buy rating. The main growth drivers are the 800G and 1.6T transceiver ramp, the expansion of production capacity, and the company's ability to turn hyperscale AI demand into revenue. I estimate these drivers can support about $1.48 billion of 2027 revenue and about $287.6 million of adjusted EBITDA if execution remains on track.
Investors searching for the biggest stock winners of 2026 may be surprised to learn they already own some of them through small-cap ETFs.
• What is going on with VTWG stock today?
This highlights that some of the strongest AI-related gains have come not from mega-cap technology companies, but from smaller firms supplying optical networking equipment, semiconductor testing systems and data-center connectivity products.
The resurgence in several high-flying Russell 2000 names has also helped narrow the performance gap between small caps and large-cap technology stocks.
For much of 2026, the Russell 2000 outperformed the Nasdaq-100 (which holds the largest tech names, including the Magnificent 7 stocks) as investors broadened their focus beyond the mega-cap AI trade.
That trend began to reverse in early May as heavyweight technology stocks regained momentum. The Nasdaq-100 has since pulled ahead and is now up roughly 21% year-to-date, compared with about 16% for the Russell 2000.
Still, the strong performance of a handful of small-cap winners suggests investor appetite for AI-related opportunities extends well beyond the largest technology companies, providing support for small-cap ETFs even as leadership shifts back toward the Nasdaq’s biggest names.
Which ETFs Had Exposure To Multiple Winners?Several ETFs show up repeatedly among the ownership lists of the year’s top-performing Russell 2000 stocks.
For investors who owned diversified small-cap growth funds at the start of the year, the gains from these stocks likely contributed meaningfully to performance despite relatively modest portfolio weightings.
The AI Supply Chain Is Expanding Beyond NvidiaThree of the five biggest Russell 2000 winners share a common thread: AI infrastructure.
Applied Optoelectronics manufactures optical networking products used in high-speed data-center connections. Aehr Test Systems supplies semiconductor burn-in and testing equipment, while MaxLinear develops connectivity and networking chips used across communications infrastructure. Their rallies suggest investors are increasingly looking beyond chipmakers and into the broader ecosystem supporting AI deployment.
Inspire Small/Mid Cap ETF (NYSE:ISMD), which holds names like Aehr, MaxLinear and Agilon Health. The fund has gained almost 21% YTD.
Bottom LineFor ETF investors, the takeaway is simple: small-cap growth funds may have provided exposure to several of the year’s biggest winners long before they became Wall Street’s latest AI success stories.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways Applied Optoelectronics is riding AI data-center buildouts, lifting demand for high-speed transceivers. AAOI expects 800G to become its biggest data-center revenue line, with demand over capacity to mid-2027. Applied Optoelectronics is qualifying more 800G products in Texas to raise U.S. shipments and meet demand. The rapid expansion of artificial intelligence infrastructure is a major tailwind for Applied Optoelectronics (AAOI - Free Report) , a supplier of optical networking products used in data centers. AI workloads require massive amounts of data to move between graphics processing units (GPUs), servers and storage systems at extremely high speeds and low latency. This demand is driving increased adoption of high-speed optical transceivers and connectivity solutions, areas where Applied Optoelectronics has established expertise. As hyperscale cloud providers continue investing billions of dollars in AI infrastructure, the need for advanced optical networking equipment is expected to rise substantially.
Applied Optoelectronics is gaining from the rising demand for its 400G and 800G solutions as enterprises worldwide transition from traditional data centers to AI-focused infrastructure. AI-driven data centers require advanced networking capabilities and high-speed optical interconnect solutions to handle significantly larger workloads, which are essential for next-generation computing architectures.
AAOI management expects 800G to become the largest data center revenue line shortly, with demand projected to exceed production capacity through mid-2027. Full qualification of additional 800G products in Texas is expected soon, enabling an increase in U.S. shipments.
The AI boom is also accelerating the transition to higher-speed networking standards such as 400G, 800G and eventually 1.6T optical modules. AI training clusters require far greater bandwidth than traditional cloud computing environments, forcing data center operators to upgrade their networking architectures. Applied Optoelectronics has been expanding the product portfolio to address these next-generation requirements, positioning it to benefit from increased spending by major cloud and AI customers. The company's vertically integrated manufacturing model may further enhance its ability to meet growing demand while maintaining cost competitiveness.
Beyond direct product sales, the proliferation of AI applications is contributing to a broader data center expansion cycle that supports long-term growth opportunities for Applied Optoelectronics. As enterprises and cloud providers deploy larger AI models and inference workloads, they must build more interconnected data center capacity, increasing the need for optical networking solutions throughout the ecosystem. If AI-related capital expenditures remain strong over the coming years, Applied Optoelectronics could see sustained demand growth, improved revenue visibility and expanded opportunities to deepen relationships with leading technology companies investing heavily in AI infrastructure.
Taking a Look at Some Other AI StocksMicronTechnology (MU - Free Report) is poised to be the key beneficiary of surging AI-related infrastructure spending, as companies continue to build out GPU clusters and AI data centers that require advanced memory solutions. AI PCs are an important part of Micron’s growth plan. An expanding partner base that includes the likes of NVIDIA, AMD and Intel, is enabling Micron to capture a larger share of the AI infrastructure market. Deepening relationship with major cloud and enterprise customers ensures stable revenue streams and reduces the risk of pricing volatility.
Teradyne (TER - Free Report) is benefiting from strong AI-related demand, which is driving significant investments in cloud AI build-out as customers accelerate production of a wide range of AI accelerators, networking, memory and power devices.
Teradyne is being aided by the growing demand for AI infrastructure, which is driving robust growth across its semiconductor test business. Teradyne expects robust growth in the semiconductor test market, particularly in the compute segment, which is projected to expand significantly due to the rapid build-out of AI data centers and the growth of edge AI.
AAOI’s Price Performance, Valuation & EstimatesShares of AAOI have surged in triple digits (% wise) over the past six months, outperforming the Zacks Electronics - Semiconductors industry’s return.
6-Month Price ComparisonImage Source: Zacks Investment Research
In terms of forward 12-month Price/Sales (P/S), Applied Optoelectronics is trading at a marginal discount compared with its industry.
Image Source: Zacks Investment Research
See how the Zacks Consensus Estimate for AAOI’s earnings has been revised over the past 90 days.
Image Source: Zacks Investment Research
AAOI’s Zacks RankAAOI currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Nvidia reaffirmed pluggable optics through 2027, extending demand visibility for AAOI's 800G and 1.6T transceivers. AAOI disclosed over $324 million of hyperscaler orders and expects 2026 revenue to exceed $1.1 billion. Management stated demand exceeds manufacturing capacity through mid-2027, making production expansion the primary growth constraint.
SUGAR LAND, Texas, June 10, 2026 (GLOBE NEWSWIRE) -- Applied Optoelectronics Inc. (NASDAQ: AAOI), a leading provider of advanced optical and HFC networking products powering AI, today announced it is providing Spectrum with its QuantumLink™ remote management software to serve as the control system for all connected 1.8GHz amplifiers across Spectrum’s footprint.
AOI’s expanding relationship with Spectrum reflects the growing convergence of hardware and software within modern broadband networks. Building on AOI’s established role supporting Spectrum’s network evolution project with connected 1.8GHz amplifiers, the addition of QuantumLink remote management software extends the collaboration into centralized network intelligence and operational control. The deployment of QuantumLink Central enables Spectrum’s machine learning and automation capabilities to drive higher network performance and resiliency.
“As broadband networks evolve toward more intelligent, software-enabled architectures, operators require integrated solutions that combine high-performance hardware with advanced remote management capabilities,” said Todd McCrum, Senior Vice President and General Manager for AOI’s Broadband Access Business Unit. “Our QuantumLink platform will give Spectrum deep operational visibility and remote control of its amplifier assets, helping reduce operational complexity, minimize truck rolls, improve response times, and enable more proactive network optimization across its footprint.”
“Spectrum is building a more scalable and resilient broadband network that can support the growing connectivity demands of our customers,” said Noel Dempsey, Senior Vice President, Field Engineering, Spectrum. “Deploying AOI’s QuantumLink remote management software across our connected 1.8GHz amplifier footprint gives us the ability to proactively monitor and manage critical network infrastructure more efficiently, helping improve service reliability, accelerate issue resolution, and support the continued evolution of our HFC network.”
Additional Resources:
QuantumLinkAOI Quantum BandwidthQuantum18 Amplifiers About AOI
Applied Optoelectronics, Inc. (AOI) is a leading developer and manufacturer of advanced optical and HFC networking products that are the building blocks for AI datacenters, CATV and broadband fiber access networks around the world. AOI supplies this critical infrastructure to tier-one customers across cloud computing, CATV broadband, telecom, and FTTH markets. The company has R&D facilities in Atlanta, GA, and engineering and manufacturing facilities at its corporate headquarters in Sugar Land, TX, as well as in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com.
Applied Optoelectronics shares are powering higher. What’s fueling AAOI momentum? Despite high volatility and a cooling broader AI market, Boloor remains bullish on AAOI. He views optical connectivity as a long-term secular winner, positioning the company as an essential data center infrastructure provider rather than a speculative chip stock.
Premarket index pressure is leaning risk-off, with the Dow (DIA) down 0.51% and the Russell 2000 (IWM) down 0.21%, which makes AAOI's upside look more stock-specific than market-driven. That divergence often shows up when a single-name narrative is pulling in incremental buyers despite weaker futures.
AAOI Stock: Key Levels and Trends to WatchAAOI is in a powerful longer-term uptrend (up 890.75% over the past 12 months), but the near-term tape is choppier: it's trading 6.9% below the 20-day SMA ($183.49) while still holding 6.8% above the 50-day SMA ($160.02). That "below short-term, above intermediate-term" posture often signals consolidation after a big run rather than a clean trend break.
RSI is the better momentum lens here, and at 47.23 it's neutral—suggesting the stock has cooled from earlier froth and is no longer technically "stretched" to the upside. In plain terms, RSI helps gauge whether buying or selling has gotten overdone, and this reading points to a reset phase instead of a momentum extreme.
The bigger-picture trend structure remains constructive with the 20-day SMA above the 50-day SMA, and the 50-day SMA above the 200-day SMA (a golden cross that occurred in August 2025). Key turning points to keep in mind: the stock tagged a 52-week high in May ($233.67), set a swing low in March, and previously saw RSI enter overbought territory in April—context that fits the idea of a high-volatility leader digesting gains.
Key Resistance: $173.50 — a nearby pivot area that can cap rebounds, sitting just above the current price zone Key Support: $160.00 — lines up closely with the 50-day SMA ($160.02), a common "trend support" reference for dip buyers AAOI Stock Price Movement Wednesday MorningAAOI Stock Price Activity: Applied Optoelectronics shares were up 10.45% at $179.90 Wednesday morning, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Optical-networking stocks are catching a bid in midday trading on Wednesday, with the group rallying together as the AI infrastructure trade reasserts itself. Applied Optoelectronics (NASDAQ:AAOI) stock is leading the pack, up 7% to $174, while Lumentum (NASDAQ:LITE | LITE Price Prediction) shares are up 5% to $859 and Coherent (NYSE:COHR) stock is trading 2% higher near $363.
The move comes after a choppy stretch for the group. All three names had pulled back sharply over the prior several sessions before today’s bounce, so investors are watching whether buyers can defend recent levels.
What’s striking is the underlying trend behind today’s intraday gains. AAOI is up 416% year to date, while LITE has gained 139% year to date and COHR has climbed 101% year to date.
AI Data-Center Demand Powers the Optics Trade The catalyst is thematic rather than company-specific. As AI clusters scale, optical interconnects and high-speed transceivers become critical infrastructure for moving massive amounts of data between AI chips and across data centers. That has turned this group into one of the most leveraged ways to play hyperscaler capex.
Applied Optoelectronics is squarely in the middle of that story. The company posted Q1 2026 revenue of $151.14 million, up 51% year over year, with the datacenter segment more than doubling to $81.4 million on its first volume shipment of 800G transceivers to a large hyperscale customer. CEO Thompson Lin pointed to “strong customer engagement around our 800G transceivers and 1.6 Tb products, particularly as AI-driven datacenter investments accelerate.”
Lumentum’s setup looks similar. The company reported Q3 FY2026 revenue of $808.4 million, up 90% year over year, with co-packaged optics and optical circuit switch backlog already topping $400 million. CEO Michael Hurlston said, “Lumentum delivered an exceptional third quarter, with revenue growing 90% year over year to a record $808 million.”
NVIDIA Halo Lifts Coherent Coherent rounds out the trade, and it now sits at the intersection of the photonics buildout and the NVIDIA (NASDAQ:NVDA) ecosystem. The company posted Q3 FY2026 revenue of $1.81 billion, up 21% year over year, with the Datacenter & Communications segment up 41% to $1.36 billion, now 75% of revenue.
The bigger story is strategic. NVIDIA invested $2 billion in Coherent, deepening a partnership on laser and optical networking products. CEO Jim Anderson framed it confidently, declaring, “As AI datacenter infrastructure continues to scale, we are rapidly expanding capacity to meet demand.”
The Group Trades as One Today’s tape underscores how tightly correlated this basket has become. When sentiment around hyperscaler spending firms up, the optics names tend to move together, and when it softens, the pullbacks are equally sharp. Today’s intraday moves illustrate just how leveraged these stocks are to the AI capex cycle.
The valuation backdrop reflects that enthusiasm. Coherent trades at a forward P/E ratio of 51x, with an analyst target price of $380.62 and a beta of 2.05. That kind of multiple leaves little room for execution stumbles.
What to Watch Into the Close The first read is whether today’s gains hold into the close, or whether the group fades again the way it did earlier this month. Trading volumes and the behavior of the broader semiconductor complex into the bell should tell the story.
Beyond today, the next anticipated catalysts are hyperscaler capex updates and any incremental NVIDIA-related news flow tied to next-generation networking. Earnings from Applied Optoelectronics, Lumentum, and Coherent will then sharpen the picture on 800G ramp velocity, co-packaged optics adoption, and capacity expansion timelines.
These remain high-beta, momentum-driven names, and investors sizing their positions should remember that big up days can both follow and precede sharp pullbacks. The AI optics thesis is intact, but the path is rarely a straight line.
Applied Optoelectronics AAOI is trading at a premium, meaning investors are willing to pay more for the stock. Based on a forward 12-month Price/Sales (P/S), AAOI trades at 8.71x, compared with the Zacks Computer and Technology sector's 6.62x.
Applied Optoelectronics (AAOI 1.34%) stock has been managing to move higher in Wednesday's trading despite a bearish backdrop for the broader market. The company's share price was up 7.6% as of 2:45 p.m. ET. Meanwhile, the S&P 500 was down 1.2%, and the Nasdaq Composite was down 1.6%.
Applied Optoelectronics stock was hit with a big sell-off yesterday, but it's rebounding in today's session. Despite recent volatility, the stock is up roughly 405% in 2026.
Image source: Getty Images.
Applied Optoelectronics stock is surging after a sell-off Networking stocks got hit hard in Tuesday's trading following bearish pressures for the broader market and a report distributed to institutional investors suggesting that the optical networking market could face near-term pressures. The report suggested that shipping for co-packaged optics, including components from leading providers, could be delayed, but Applied Optoelectronics stock is seeing bullish rebound trading in today's session.
Today's Change
(
-1.34
%) $
-2.35
Current Price
$
172.78
What does the broader market picture mean for Applied Optoelectronics? Today's big gain for Applied Optoelectronics stock is eye-catching in light of bearish momentum for the broader market. Investors have broadly been selling out of stocks in response to the Bureau of Labor Statistics' Consumer Price Index (CPI) inflation report for May and indications that the war in Iran could be poised for another escalation.
Potential market volatility connected to SpaceX's June 12 initial public offering is also spurring volatility. With trading looking shaky across the stock market, there's a risk that Applied Optoelectronics could see more big volatility in the near term.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Trump Media and Technology Corp., which operates the social media platform Truth Social, has named Kevin McGurn as interim CEO to succeed Devin Nunes.
McGurn, a former executive at T-Mobile USA, Vevo and Hulu, has been an advisor to the company since December, 2024.
Nunes, a former congressman, has served as CEO since the company’s inception. In addition to Truth Social, the company operates the streaming service Truth+ and the financial services brand Truth.Fi.
In March, TMTG reported a $712 million loss on net revenue of $3.7 million. It reported assets of $2.6 billion.
The stock, operating with the symbol of the president’s initials, DJT, closed at $9.82 on Tuesday, down 3.7%. Since Trump was reelected in 2024, it reached a high of $40.03 on Jan. 17, 2025.
In a statement, Donald Trump Jr. said, “I want to thank Devin Nunes for his dedicated service to the Company over the past four years, and congratulate Kevin McGurn on his appointment as Interim CEO. Kevin brings deep experience across media, technology, and capital markets, as well as a strong understanding of Trump Media’s operations and strategic priorities. His familiarity with the Company and alignment with our leadership team uniquely position him to guide Trump Media through this important period.”
The company has, among other things, partnered with Crypto.com and, late last year, announced a merger with fusion power company TAE Technologies, with the deal expected to close in mid-2026. In February, they announced the potential spinoff of businesses including Truth Social.
In a statement, McGurn said that the president “founded Truth to give all Americans a platform for free speech, and the Company is poised to take off and meet that vital challenge and opportunity.”
“In carrying President Trump’s unique, singular vision and message, Truth Social stands for the most powerful brand and voice in history of social media and beyond. I look forward to building on the strong foundation established by the team, ensuring a smooth leadership transition, executing on our strategic priorities, and positioning our media assets for their next phase of growth.”
The Trump business behind Truth Social is replacing a former congressman and big supporter of the U.S. president as the leader of the social media platform after a stock collapse that wiped out billions in investor wealth.
Devin Nunes, a former California congressmen in Donald Trump’s first term, is being replaced temporarily by digital media executive Kevin McGurn as chief executive officer. The company, Trump Media & Technology, didn’t give a reason for Nunes leaving or provide a timeline for his permanent replacement.
After soaring shortly before Trump’s re-election in November 2024, stock in the company plunged 67%, wiping out more than $6 billion in investor wealth.
Trump Media was formed by the Trump family as an alternative to social media giants that had barred him from posting on their platforms after the January 6, 2021 Capitol riots. It said it would not only take on Facebook and Twitter as a “free speech” alternative, but eventually could become a media giant competing with streaming services such as Netflix.
The stock soared, but it never gained traction with a wide audience despite the president’s frequent use of it for major political announcements, slammed by government ethics experts as a conflict of interest with the presidency.
Since it went public two years ago, Trump Media has lost more than $1.1 billion. Nunes got total compensation of $47 million in 2024, the last year for which figures are available.
The new CEO McGurn said in statement that the company was “poised to take off.”
“In carrying President Trump’s unique, singular vision and message, Truth Social stands for the most powerful brand and voice in history of social media and beyond,” he said.
The Trump Organization didn’t immediately responded to a request for comment.
The company has recently branched into cryptocurrency and another hot business, prediction markets. The latter are online betting venues where people can wager on sports, entertainment and political events.
Both cryptocurrencies and prediction markets have gotten boosts from the Trump administration, in terms of lighter regulation and outright promotion. Last year, for instance, the Trump established a national bitcoin reserve, pushing up the value of that currency.
McGurn, has worked at NBC Universal, Hulu and DoubleClick, among other companies, according to his LinkedIn profile. He is also the CEO of a new shell company that Trump’s two oldest sons, Donald Jr. and Eric, joined last year to buy U.S. manufacturers. That company originally stated in regulatory filings that it would be targeting businesses hoping to tap federal contracts, which would be awarded by the same government run by their father.
The Trump Organization and the White House have repeatedly denied that there are conflicts of interest between Trump’s role as president and the family business.
The final deadline for Fast Company's Next Big Things in Tech Awards is Friday, June 12, at 11:59 p.m. PT. Apply today.
Key Takeaways The Trump-family owned parent company of Truth Social tapped a new interim chief after Devin Nunes, a former California congressman, stepped down on Wednesday.Trump Media & Technology Group's market capitalization, over $10 billion at its peak, is now at about a quarter of that. Get personalized, AI-powered answers built on 27+ years of trusted expertise.
Trump Media & Technology (DJT) has taken investors on a wild ride. Unfortunately for them, it's mostly been downhill.
And it's unclear when that might change, with the stock extending its slide as the company—parent of social media platform Truth Social, part-owned by President Donald Trump—appears to plotting a new path under new leadership. Trump Media earlier this week appointed Kevin McGurn its interim CEO after its longtime chief, former Congressman Devin Nunes, stepped down.1
Trump Media, then led by Nunes, seemed on the upswing as Trump clinched a second term, with a market capitalization around $9 billion. More recently, it has reported steep financial losses, and announced a deal with fusion energy company TAE Technologies, plans to spin Trump Media businesses including Truth Social into another public company, and the possibility of more deals on the way.
Investors haven't seen much that they like, with the stock generally falling since Trump's reelection and the company's market value now around $2.5 billion.
WHY THIS MATTERS TO YOU Though Trump Media started out on a pretty path after its listing debut in March 2024, and shares surging on President Trump's winning a second term—its future now would appear murkier.
Nunes on Truth Social thanked President Trump, saying the time was "appropriate" for McGurn to "take over the Company's leadership and steer Trump Media through its current transition phase."2 Eric Swider, who was chief of the blank-check company that merged with Trump Media to land "DJT" on public exchanges in 2024, resigned from the board in early April. 3
Truth Social continues to be a vital communications organ for the president—but its monthly active users on iOS and Android have fallen 9% year-over-year to a little over 2 million, while desktop and mobile web audiences have declined 27% to 4.6 million users, according to estimates from digital intelligence platform Similarweb. Its daily active users, at just under 320,000, are about a tenth of the next biggest platform, Blusky Social, and a sliver of X's roughly 129 million, according to Similarweb data.
Trump Media in February reported 2025 revenue of about $3.7 million and a net loss of more than $712 million, most of which the company said was due to unrealized losses from its digital assets and related securities.4 At the end of 2025, the company said, it had about $2.5 billion in cash, restricted cash, short-term investments, stock, note receivables, digital assets and pledged digital assets.
McGurn has served as an adviser to Trump Media since late 2024. He was also the chief of at least two blank- check companies that have been in deal talks with Trump Media: Yorkville Acquisition Corp. (MCGA), which per an August announcement is intended to form Trump Media Group CRO Strategy, a digital asset treasury focused on cronos, crypto that is held on Trump Media's balance sheet, and Texas Ventures Acquisition III (TVA), which Trump Media said in February was in "discussions" to merge with Trump Media businesses including Truth Social and other of its businesses after they were spun off.5
A merger between spun-off Trump Media businesses and Texas Ventures would occur only after Trump Media's merger with TAE, a company aspiring to make fusion energy a commercial reality, according to the companies.6 7
Trump Media has yet to offer much explanation for the management change or detail regarding what could follow. A Trump Media spokesperson directed Investopedia to official statements and did not directly address emailed questions regarding the resignation of Swider, the status of the pending deals announced by Trump media, and whether McGurn would be handling those deals.
For now, investors are backing off. The shares recently traded below news of the latest round of deals landed—though holding above 2026, and all-time, lows below $9 apiece.
After a significant jump between April 27 and 28, Trump Media & Technology (NASDAQ: DJT) stock short volume ratio inched higher and ended the month at its highest value in at least two weeks.
Specifically, after hitting its recent low of 37.11, the metric soared to 60.18 within a single day and continued climbing to 61.63 on April 30.
DJT stock short volume ratio. Source: Finbold Notably, the April 27 bottom coincided with one of DJT stock’s highest closing prices of the month – $9.95 – and the subsequent rise in bearish bets accompanied a significant price drop.
Thus, the most recent reading appears to indicate that investors estimate that Trump Media shares are about to plunge further in May, though it simultaneously raises the possibility that a significant short squeeze is imminent.
Is a squeeze imminent for DJT stock short-traders? The possibility that DJT stock short-sellers are about to get liquidated is increased by the equity’s 2026 tendency to trade together with major moves made by other major assets, at least in the short term.
Indeed, while noticeably more volatile, Trump Media appears to have followed the wider market into the late January downturn, the Iran war crash, but also the upward bounce from the bottom between March 27 and 30.
Still, while event-driven, the equity’s performance also demonstrated it is backed by less long-term confidence than most of the prominent technology companies.
Specifically, while the benchmark S&P500 index continued trading higher from the recent low and ended the month at a new all-time high (ATH), DJT reached its 30-day high of $10.26 already on April 17 and ended the period at $9.17.
Trump media stock price one-month chart. Source: Finbold Why a Trump stock short squeeze in May is unlikely Additionally, both the recent events and technical analysis (TA) appear to be ruling out an imminent short squeeze.
Overall readings for DJT, whether based on the last month, week, or day, are leaning toward a ‘Sell’ recommendation, with moving averages (MA) being rather decisive and oscillators only occasionally painting a bullish picture, per the data Finbold retrieved from TradingView on May 1.
DJT stock technical analysis. Source: TradingView Simultaneously, while a conclusive U.S. victory against Iran could drive the Trump stock higher, a final peace agreement appears as elusive as a decisive military operation.
Still, the recent increase in oil prices and the President’s upcoming visit to China – scheduled for mid-May – represent a point of pressure that could lead to a sudden diplomatic breakthrough and generate a sudden tailwind rather than continuing to produce headwinds.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Kevin McGurn helped drive the company's unexpected foray into fusion energy. Now, he will have to figure out how to manage a diverse group of businesses as its CEO.
The pitch was simple: buy the ticker, ride the brand. Two years after Trump Media & Technology Group (NASDAQ:DJT) went public in March 2024 via a merger with Digital World Acquisition Corp, the math on that trade is brutal for people who bought near the top.
The stock closed at **$8.77 on May 12, 2026**, down **77.47%** from the $38.94 it traded at on March 1, 2024. Over the past year, DJT has shed 64.12%, and the market cap now sits at roughly $2.43 billion.
The Insider Versus Retail Math At the peak of 2024 euphoria, Donald Trump’s personal stake in TMTG climbed past $4 billion, per Forbes’ 2025 estimate that pegged his total wealth at $7.3 billion. Insider ownership stands at 42.62%. Founders held shares acquired at near-zero cost. Retail investors who chased headlines paid market price and absorbed almost all downside as the ticker retraced.
This is the recurring lesson of brand-wrapped equities: insiders do far better than those who bought the name.
Fundamentals Never Showed Up The company recently released its **Q1 2026 earnings results**, reporting a **net loss of $405.9 million** for the three-month period ending March 31. This follows a full-year 2025 where revenue was just $3.68 million against a $711.2 million loss. Notably, $368.7 million of the Q1 loss was attributed to non-cash unrealized losses on digital assets, reinforcing the company’s status as a volatile bitcoin proxy.
The valuation math remains severe. Price-to-sales is astronomical, and revenue per share is negligible. While former CEO Devin Nunes framed a “balance sheet story” in February, the fundamentals of an operating business are still missing. The underlying social platform generated under $0.9 million of revenue in Q1 2026, continuing a trend of stagnant growth.
The “McGurn Pivot” and Retail Sentiment The narrative took a new turn on **April 21, 2026**, when TMTG appointed **Kevin McGurn as Interim CEO**. This leadership transition occurred just as the company doubled down on its focus toward the TAE Technologies fusion merger to justify its multi-billion dollar valuation.
Reddit traffic reflects the growing skepticism. After a brief bullish spike around the merger announcement, sentiment collapsed. By May 12, 2026, sentiment on r/wallstreetbets remained firmly bearish (index of 16), with retail discussion focused on the “retail dilution” paradox: while the company has grown its cash position to $2.2 billion through equity maneuvers, the per-share value for everyday investors continues to evaporate.
What To Watch For a long-term portfolio, the questions are clarifying. Is DJT a media company, a bitcoin proxy, or a holding-company experiment? With quarterly revenue under $1 million, the operating business does not yet exist at scale. The treasury and the brand are the only pillars holding up the stock. As the company navigates a leadership transition and a complex fusion merger, the fundamentals supporting a $2.4 billion equity are not present. Treat the ticker accordingly.
~ Total Assets of $2.2 Billion and Over $2 Billion in Financial Assets* ~
~ $17.9 Million Cash Provided by Operating Activities with Fourth Consecutive Quarter of Positive Operating Cash Flow ~
~ Truth Social, Truth+ Enhancements Continue as TMTG Moves toward Prospective Merger with TAE Technologies ~
SARASOTA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, the video streaming service Truth+, and the financial services and FinTech brand Truth.Fi, is announcing its financial results for the fiscal quarter ending on March 31, 2026, and is filing its Form 10-Q with the Securities and Exchange Commission (the “SEC”) today.
TMTG closed the first quarter of 2026 with total assets of $2.2 billion and financial assets of approximately $2.1 billion comprising cash, restricted cash, short-term investments, equity securities, note receivable and accrued interest, digital assets, and digital assets pledged—nearly tripling the Company’s $759.0 million in financial assets held at the end of the first quarter of 2025. The Company also announced its fourth consecutive quarter of positive operating cash flow, posting $17.9 million of cash provided by operating activities for the first quarter.
Supported by its strong balance sheet, the Company is continuing to pursue all its strategic priorities, including expanding and enhancing its flagship Truth Social and Truth+ platforms. Truth Social is currently developing or testing numerous new features including:
Discussion and share features for predictions contracts, provided in cooperation with Crypto.com | Derivatives North America (CDNA).A dedicated feature for sports information and discussion.Boosted truths allowing for increased visibility of specific posts.Enhancements to the platform’s interoperability with Truth+.Continued expansion of the use of artificial intelligence to assist the platform’s performance. The Truth+ video streaming platform had robust enhancements in the first quarter, focusing on expanding content and improving the platform’s ease of use, including:
Expanding live TV entertainment options with the addition of new channels including Nothing But Sportz, Retro, and In Touch.Expanding international offerings by adding i24 English Israel, Azores TV, and Western Bound Portugal, while negotiations are ongoing to incorporate additional international programming options.Enhancing the look and ease of use across the platform, including for the TV guide, on demand programming, carousels, and connected TVs.Introducing push notifications for Truth+ app users.Simplifying the onboarding process and reducing friction for new users. TMTG Interim Chief Executive Officer Kevin McGurn said, “Trump Media is using its strong balance sheet and positive operating cash flow to continue growing all our businesses and platform infrastructure. Even as we work toward advancing our proposed merger with TAE Technologies as quickly as possible, we’re identifying new growth opportunities and new ways to increase shareholder value. Truth Social remains a bastion of free speech with innovative enhancements coming soon, and I look forward to rapidly growing our Truth Social and Truth+ communities and building out these powerful, uncancellable platforms for free expression.”
Aside from its $2.1 billion in financial assets and $17.9 million in positive operating cash flow, the Company reported a $405.9 million net loss and a $387.8 million Adjusted EBITDA* loss for the first quarter of 2026, the vast bulk of which was non-cash losses including unrealized losses on digital assets, digital assets pledged, and equity securities ($368.7 million), accreted interest ($11.5 million), and stock based compensation ($11.8 million). The Company posted $0.9 million in revenue, as it continues to focus on expanding its infrastructure and audience to prepare for future monetized features.
* Financial Assets, Positive Operating Cash Flow and Adjusted EBITDA are Non-GAAP Financial Measures, the definitions which can be found in the Use of Non-GAAP Financial Measures section at the end of this release. A reconciliation of Adjusted EBITDA to the most comparable GAAP measure can also be found in the Use of Non-GAAP Financial Measures section at the end of this release
About TMTG
The mission of Trump Media is to end Big Tech’s s assault on free speech by opening up the Internet and giving people their voices back. Trump Media operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations; Truth+, a TV streaming platform focusing on family friendly live TV channels and on-demand content; and Truth.Fi, a financial services and FinTech brand incorporating America First investment vehicles.
Investor Relations Contact
Shannon Devine (MZ Group | Managing Director - MZ North America) Email: [email protected]
Important Information About the Proposed Transaction and Where to Find It
In connection with TMTG’s merger with TAE Technologies (the “Proposed Transaction”), TMTG intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 to register the common stock of TMTG (“TMTG Shares”) to be issued in connection with the Proposed Transaction. The registration statement will include a document that serves as a proxy statement and prospectus of TMTG and consent solicitation statement of TAE (the “proxy statement/prospectus and consent solicitation statement”), and TMTG will file other documents regarding the Proposed Transaction with the SEC. This document is not a substitute for the registration statement, the proxy statement/prospectus and consent solicitation statement, or any other document that TMTG may file with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND CONSENT SOLICITATION STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TMTG AND TAE, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO, AND RELATED MATTERS.
After the registration statement has been declared effective, a definitive proxy statement will be mailed to the shareholders of TMTG (the “TMTG Shareholders”) and a prospectus and consent solicitation statement will be sent to the stockholders of TAE. Investors and security holders will be able to obtain free copies of the registration statement and the proxy statement/prospectus and consent solicitation statement, as each may be amended or supplemented from time to time, and other relevant documents filed by TMTG with the SEC (if and when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by TMTG, including the proxy statement/prospectus and consent solicitation statement (when available), will be available free of charge from TMTG’s website at tmtgcorp.com under the “Investors” tab.
Participants in the Solicitation
TMTG and certain of its directors and executive officers and TAE and certain of its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the TMTG Shareholders with respect to the Proposed Transaction under the rules of the SEC. Information regarding the names, affiliations and interests of certain of TMTG’s directors and executive officers in the solicitation can be found by reading TMTG’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 27, 2026 (as amended on April 30, 2026), TMTG’s subsequent Quarterly Reports on Form 10-Q filed with the SEC, TMTG’s definitive proxy statement for the 2025 annual meeting of shareholders filed with the SEC on March 18, 2025 and the proxy statement/prospectus and consent solicitation statement and other relevant materials filed with the SEC in connection with the Proposed Transaction when they become available. Free copies of these documents may be obtained as described in the paragraphs above. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the TMTG Shareholders in connection with the Proposed Transaction, including a description of their direct and indirect interests, by security holdings or otherwise, will also be set forth in the proxy statement/prospectus and consent solicitation statement and other relevant materials when filed with the SEC.
Cautionary Statement About Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the U.S. federal securities laws, including regarding, among other things, the plans, strategies, and prospects, both business and financial, of TMTG, and its current expectations and projections about future events such as TMTG’s Proposed Transaction with TAE. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words, and the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events or conditions that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause future results, performance or achievements expressed or implied by the forward-looking statements to differ materially from the forward-looking statements in this communication, including, but not limited to, risks related to TMTG’s or TAE’s ability to demonstrate and execute on commercial viability of its technology; legal proceedings; ability to obtain financing on acceptable terms or at all; changes in digital asset valuations; disruption to TMTG’s operations; TMTG’s ability to develop and maintain key strategic relationships; competition in TMTG’s industry; ability to access required materials at acceptable costs; delays in the development and manufacturing of fusion power plants and related technology; ability to manage growth effectively; possibility of incurring losses in the future and not being able to achieve or maintain profitability; potential generation capacities of specific reactor designs; regulatory outlook; future market conditions; success of strategic partnerships; developments in the capital and credit markets; future financial, operational and cost performance; revenue generation; demand for nuclear energy; economic outlook and public perception of the nuclear energy industry; changes in laws or regulations; ability to obtain required regulatory approvals on a timely basis or at all; ability to protect intellectual property; adverse economic or competitive conditions; and other risks and uncertainties. In addition, TMTG cautions you that the forward-looking statements contained in this communication are subject to the following factors: (i) the occurrence of any event, change or other circumstances that could delay site selection or the Proposed Transaction or give rise to the termination of the agreements related thereto; (ii) the outcome of any legal proceedings that may be instituted against TMTG or TAE with respect to site selection or the Proposed Transaction; (iii) the inability to complete the Proposed Transaction due to the failure to obtain approval of the shareholders of TMTG or TAE, or other conditions to closing in the merger agreement; (iv) the risk that the Proposed Transaction disrupts TMTG’s current plans and operations as a result of the announcement of the Proposed Transaction; (v) TMTG’s ability to realize the anticipated benefits of the Proposed Transaction, which may be affected by, among other things, competition and the ability of TMTG to grow and manage growth profitably following the Proposed Transaction; and (vi) costs related to the Proposed Transaction, site selection or construction. The forward-looking statements in this press release are based upon information available to TMTG as of the date of this press release and, while TMTG believes such information forms a reasonable basis for such statements, these statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Except as required by applicable law, TMTG does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in TMTG’s periodic filings with the SEC, including TMTG’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (as amended on April 30, 2026), TMTG’s subsequent Quarterly Reports on Form 10-Q and in the Form S-4, when filed, and in other documents filed by TMTG from time to time with the SEC. TMTG’s SEC filings are available publicly on the SEC’s website at www.sec.gov. These filings do or will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. There may be additional risks that TMTG presently knows or that TMTG currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and TMTG assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. TMTG does not give any assurance that TMTG will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by TMTG or any other person that the events or circumstances described in such statement are material.
No Offer or Solicitation
This communication is not intended to and does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Use of Non-GAAP Financial Measures
The Company uses certain Non-GAAP financial measures, which Financial Assets, Positive Operating Cash Flow and Adjusted EBITDA, as we believe these measures can provide meaningful information regarding our operating performance. These Non-GAAP measures should be evaluated in addition to and not as a substitute for our financial results presented in accordance with U.S. GAAP.
Financial Assets are our Total Assets comprised solely of cash, restricted cash, short-term investments, equity securities, note receivable and accrued interest, digital assets, and digital assets pledged. Positive Operating Cash Flow is our cash provided by operating activities. Adjusted EBITDA is a non-GAAP financial measure defined as net income plus interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation. The Company presents Adjusted EBITDA because management believes that it can be a useful financial metric in understanding the Company’s earnings from operations. Adjusted EBITDA is not a measure of the Company’s financial performance under GAAP and should not be considered as an alternative to net income or any other performance measure derived in accordance with GAAP.
A reconciliation of Adjusted EBITDA to our most directly comparable GAAP financial measures appears below.
Three Months
Ended March 31 2026 2025 Net loss $(405,884.2) $(31,726.6)Interest (income)/expense, net 4,239.6 (7,808.4)Depreciation & amortization 1,866.4 1,779.2 Stock-based compensation 11,829.6 17,851.7 Income taxes 98.8 - Adjusted EBITDA $(387,849.8) $(19,904.1)
Trump Media & Technology Group Corp. (NASDAQ:DJT) on Friday reported strong financial results, including total assets of $2.2 billion and $17.9 million in cash provided by operating activities.
This positive momentum follows the company’s ongoing efforts to enhance its platforms, particularly Truth Social and Truth+, as it moves toward a prospective merger with TAE Technologies, which has contributed to investor optimism about its growth potential.
In its recent earnings report for the first quarter of 2026, Trump Media & Technology Group announced a net loss of $405.9 million, largely attributed to non-cash losses.
Despite this, the company highlighted its fourth consecutive quarter of positive operating cash flow, indicating a solid operational foundation as it seeks to expand its audience and platform capabilities.
The company reported first-quarter earnings per share of $1.47 loss. The company posted $0.9 million in revenue. It said it continues to focus on expanding its infrastructure and audience to prepare for future monetized features.
The broader market on Friday saw positive movement, with the S&P 500 up 0.85% and the Nasdaq gaining 2.47%. This general market strength may have bolstered investor sentiment towards Trump Media, aligning its performance with the upward trends in technology stocks.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch focuses on its social media platform, Truth Social, which encourages open and honest conversation without discriminating against political ideology.
The company matters in the current context as it continues to build its brand and user base while navigating the complexities of the digital media landscape. With a strong balance sheet and positive cash flow, Trump Media is well-positioned to pursue growth opportunities and enhance shareholder value.
Benzinga Edge RankingsBelow is the Benzinga Edge scorecard for Trump Media & Technology Group, highlighting its strengths and weaknesses compared to the broader market:
– Momentum: Weak (Score: 2.39) — Stock is underperforming the broader market.
The Verdict: Trump Media & Technology Group’s Benzinga Edge signal reveals a weak momentum profile, suggesting that the stock is struggling to gain traction in a competitive market. Investors should be cautious as the company works to stabilize its performance and leverage its operational strengths.
Price ActionDJT Stock Price Activity: Trump Media & Tech Gr shares were up 0.22% at $8.95 on Friday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Trump Media & Technology Group Corp. has seen severe strategic and executional missteps under former CEO Devin Nunes, with minimal revenue and an enterprise value near $1.3 billion. DJT's operating business is essentially nonexistent, with Q1 advertising revenue down 25% year-over-year to $617,000 and negligible growth across all segments. Leadership change brings cautious optimism, but the board and interim CEO McGurn lack clear public company and capital allocation expertise.
Trump Media & Technology reported Q1 revenues of $871K, up just 6% year-over-year, with losses ballooning to $405.8 million. DJT's expenses far outpace revenues, and the company remains deeply unprofitable even excluding non-cash items. Despite $1.87 billion in cash and investments, liquidity is constrained by locked-up assets and rising debt; positive cash flow in Q1 was driven by delayed payables.
President Donald Trump scooped up shares of artificial intelligence software maker Palantir weeks before he famously lauded the stock, with its ticker symbol, on his social media platform Truth Social, according to records released this week by the U.S. Office of Government Ethics.
The records show thousands of transactions during the first quarter totaling hundreds of millions of dollars, with each trade listed as a price range.
During the first three months of the year, Trump purchased between $247,008 and $630,000 worth of stock in the now Miami-based AI company, the documents show.
In March alone, Trump made at least seven purchases of Palantir totalling as much as $530,000.
The following month, Trump praised Palantir on Truth Social as shares suffered their worst week in over a year. That came as the software selloff accelerated amid the Iran war and the company caught the ire of famed short-seller Michael Burry.
"Palantir Technologies (PLTR) has proven to have great war fighting capabilities and equipment," Trump wrote on the social media platform at the time. "Just ask our enemies!!!"
The company's tools have reportedly been used to identify targets in Iran.
Several transactions were denoted as "unsolicited," indicating that the move wasn't done by recommendation of a broker or financial advisor.
"President Trump's investment holdings are maintained exclusively through fully discretionary accounts independently managed by third-party financial institutions with sole and exclusive authority over all investment decisions. Trades are executed and portfolios are balanced through automated investment processes and systems administered by those institutions," a Trump Organization spokesperson said in a statement.
Trump, his family and the Trump organization don't play a "role in selecting, directing, or approving specific investments," they added.
"They receive no advance notice of trading activity and provide no input regarding investment decisions or portfolio management of any kind," the spokesperson said.
White House spokesman David Ingle said the president's assets are in a trust managed by his children and, "There are no conflicts of interest."
Palantir did not respond to a request for comment.
The defense tech company is among a batch of such firms currying favor with the president during his second stint in the White House, as Trump accelerates the military's push for modernization.
Read more CNBC tech newsBezos opens up about AI startup Prometheus after $12 billion raise: 'We're not being secretive'DoorDash lets customers use photos, prompts to order food and book reservations in latest AI pushAs OpenAI leans into enterprise business, Apple and Google set sights on the massesPalantir's Karp says businesses are 'unhappy' with the frontier AI labsCEO Alex Karp, a vocal proponent of the U.S. military, has backed the new administration, despite previous contributions to President Joe Biden's campaign, and the company is disrupting the traditional defense contractor system dominated by major firms like Lockheed Martin and Northrop Grumman.
Last year, Palantir sponsored Trump's military parade held in June for the U.S. Army's 250th anniversary. Other tech companies also reportedly sponsored the event.
The OGE records released this week show that Trump has been active in the stock market during the early months of 2026. That included selling as much as $5 million worth of Palantir on Feb. 10. Trump made several other sales of Palantir shares over about two weeks.
But Palantir wasn't the president's only big tech trades.
In February, the president bought between $1 million and $5 million worth of AI chipmaker Nvidia. About a week later, the company expanded its AI deal with Meta Platforms.
That month, he scooped up between $1 million and $5 million worth of ServiceNow, Workday, Oracle and Microsoft during the software selloff earlier this year.
Records also show the president bought upwards of $1 million worth of Amazon, Apple and Broadcom.
HomeEconomy & PoliticsWashington WatchWashington WatchTrump Media & Technology is set to merge with a fusion power company, as the broader fusion sector is seeing new regulations and receiving boosts from the White HousePublished: May 18, 2026 at 10:00 a.m. ET
Trump Media & Technology Group is pivoting toward nuclear fusion, a corner of the energy industry that has the Trump administration’s support. Photo: MarketWatch photo illustration/Getty Images, TAE, iStockphotoIn October, the Trump administration released a “Fusion Science and Technology Roadmap” to support the construction of commercial fusion power plants as soon as the 2030s. It may not exactly resemble a Manhattan Project for nuclear fusion, but the road map indicated the federal government would support a constellation of American fusion companies and no longer treat them like an academic project.
Among several approaches, the road map pointed to a unique reactor concept — field-reversed configurations, “which could significantly reduce the cost of fusion power.” It also referenced aneutronic fuels as being a potential source of “perhaps the greatest cost savings.”
The effort to launch Truth Social-branded cryptocurrency exchange-traded funds has come to an abrupt stop after Yorkville America Digital, LLC, which was the sponsor of the ETFs application, wrote to the US Securities and Exchange Commission (SEC) requesting the withdrawal of the application.
Yorkville America Digital indicated that the decision was linked to a broader restructuring of its ETF plans and a shift toward a different regulatory framework.
The filings covered a proposed spot Bitcoin ETF and a combined Bitcoin and Ethereum ETF tied to Trump Media & Technology Group, the parent company of Truth Social.
The withdrawal came before the SEC reached a final decision on the applications, ending months of speculation around the products and their potential entry into the growing crypto ETF market.
The withdrawal also arrives at a time when the US spot crypto ETF market has become increasingly crowded.
Since the approval of spot Bitcoin ETFs in January 2024, large asset managers including BlackRock, Fidelity, and Grayscale have attracted billions of dollars in investor inflows, making it difficult for new issuers to gain market share.
The Truth Social ETF applications had already faced delays from the SEC before the withdrawal was submitted.
Regulators previously postponed their decisions as part of the standard review process applied to crypto-related investment products.
The proposed funds aimed to provide direct exposure to Bitcoin and Ethereum through regulated exchange-traded structures.
Spot crypto ETFs hold the underlying digital assets directly rather than relying on futures contracts.
Interest in these products surged after the SEC approved the first batch of spot Bitcoin ETFs in early 2024.
According to data from SoSoValue, spot Bitcoin ETFs in the United States have collectively recorded tens of billions of dollars in cumulative net inflows since launch, led by BlackRock’s iShares Bitcoin Trust and Fidelity Wise Origin Bitcoin Fund.
However, entering the market at this stage presents major challenges.
Several established ETF issuers have already lowered management fees in an attempt to attract investors.
Some funds even launched with temporary fee waivers to gain traction quickly.
Bloomberg ETF analyst James Seyffart said the competitive environment likely played a role in the withdrawal decision.
He noted that newer entrants face an uphill battle when competing against firms with established distribution networks, larger capital bases, and stronger institutional relationships.
The Truth Social filings also attracted attention because of their political connections.
Trump Media & Technology Group has remained closely tied to US President Donald Trump, making the ETF applications more visible than many other crypto investment proposals currently under SEC review.
Yorkville America Digital reportedly indicated that the withdrawal was part of a broader strategy change involving the legal structure of future investment products.
The original filings were structured under the Securities Act of 1933, which is commonly used for commodity-based ETFs, including spot Bitcoin funds.
The revised direction appears to focus on products governed under the Investment Company Act of 1940 instead.
The two frameworks operate differently and carry separate regulatory requirements.
Funds organised under the 1940 Act are often associated with stricter investor protection rules and different portfolio management standards.
While no replacement filings have been announced, the change suggests the companies may still be exploring crypto-related investment products through an alternative structure.
Eric Swider clarifies his April 2026 departure from the Trump Media board and reaffirms he left on good terms.
Veteran SPAC and governance leader now dedicating his full attention to Rubidex and its next phase of strategic growth and capital-markets preparation.
Rubidex is building foundational infrastructure for secure distributed intelligence, enabling trusted AI, intelligent operations, and emerging Reality Intelligence across enterprise, infrastructure, and digital systems.
MIAMI, May 21, 2026 (GLOBE NEWSWIRE) -- Eric Swider, a veteran public-company and SPAC executive who played a central role in the transaction that brought Truth Social to the public markets, is clarifying that he stepped down from the board of Trump Media & Technology Group (Nasdaq: DJT) (or “Trump Media”) earlier this year in order to devote his time and energy to Rubidex and its next phase of growth, including its broader strategic and capital-markets development. Trump Media disclosed in an SEC filing that Swider’s resignation became effective April 6, 2026, and that it did not arise from or relate to any dispute with management or the board.
Swider’s departure marks a significant transition given the role he played in the success of the Truth Social de‑SPAC and its path to the public markets. He served as interim chief executive officer of Digital World Acquisition Corp. (“DWAC”) beginning in March 2023, became chief executive officer in July 2023, and had served on DWAC’s board since September 2021, placing him at the center of the process that ultimately brought Trump Media to the public market in 2024.
Over the course of his career, Swider has built a reputation as a disciplined operator with deep experience across SPACs, governance, and special situations. In addition to leading DWAC through one of the most closely watched de‑SPAC transactions in recent years, he served as a director of Benessere Capital Acquisition Corp., founded Renatus Advisors, and has advised clients on complex legal, strategic, and operational matters.
Rubidex: Foundational Infrastructure for Secure Distributed Intelligence
Eric Swider co-founded Rubidex and has served as Chief Executive Officer since January 2020. Rubidex is the foundational infrastructure platform powering secure distributed intelligence - enabling enterprises, institutions, and operational environments to turn sensitive data into trusted intelligence for AI, automation, and intelligent operations without giving up privacy, ownership, or control.
The company's platform extends across secure distributed intelligence and a growing suite of applications built on one foundational infrastructure layer, including GridLock for critical infrastructure intelligence, BMSIntel for building intelligence, and RubiVault for trusted data environments. Rubidex provides the trust infrastructure that allows data, identity, and intelligent operations to work together securely across enterprise systems, critical infrastructure, buildings, and digital environments - enabling sensitive information to become operationally useful, not just protected.
“It has been an honor to serve on the board of Trump Media and to support Truth Social during such a pivotal chapter in its growth,” said Eric Swider. “I stepped down earlier this year on good terms and with great respect for the company, its leadership, and its mission. I am now fully focused on Rubidex and the opportunity ahead as we build foundational infrastructure for secure distributed intelligence - infrastructure designed to help organizations govern, protect, and activate sensitive information across enterprise, infrastructure, and digital environments.”
Swider brings more than two decades of leadership experience across governance, finance, operations, and high‑stakes execution. A U.S. Navy veteran with specialized nuclear engineering training, he has also worked across finance, industrial operations, energy, private equity, and data security - experience Rubidex believes is central to its next phase of strategic growth and capital‑markets development.
About Rubidex
Rubidex is building the foundational infrastructure layer for secure distributed intelligence. The company provides the trust layer that allows data, identity, intelligent operations, and emerging Reality Intelligence systems to work together securely across enterprises, infrastructure systems, and digital environments. By keeping sensitive data encrypted, governed, and auditable at the source, Rubidex enables organizations to deploy high-value information into AI, automation, and operational intelligence without giving up privacy, ownership, or control. This positions Rubidex as a category-defining infrastructure platform for a world where secure intelligence, data sovereignty, trusted operations, and Reality Intelligence must scale together. For more information, visit: https://rubidex.ai.
About Trump Media
The mission of Trump Media is to end Big Tech’s assault on free speech by opening up the Internet and giving people their voices back. Trump Media operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations; Truth+, a TV streaming platform focusing on family‑friendly live TV channels and on‑demand content; and Truth.Fi, a financial services and FinTech brand incorporating America First investment vehicles.
While the shares of Trump Media & Technology Group (NASDAQ: DJT) have lost much of their luster since the 2024 Presidential election and possibly entered terminal decline earlier in 2026 by crashing below the $10 threshold, DJT retains the potential for a brief but powerful rally.
DJT stock price one-year chart. Source: Google Specifically, between its middling quarterly filings and links with the incumbent U.S. commander-in-chief, the company has arguably become the most prominent political meme stock in the market.
Such a view of the equity was reinforced in 2024 as the DJT share price tracked Donald Trump’s odds of victory against Kamala Harris, and in the summer of 2025, when the presidential firm rallied around July 4.
With Independence Day 2026 fast approaching and Trump Media showing it has the potential to rally already, as recently as December, Finbold consulted ChatGPT’s advanced artificial intelligence (AI) on whether making a bet on a celebratory upsurge has any legs to stand on.
ChatGPT estimates the likelihood of a July 4 Trump stock rally After analyzing DJT shares and concluding that the most recent earnings report – the one that recorded losses greater than $400 million and revenue smaller than $1 million – the AI model dismissed the odds of a rally based on fundamentals.
Indeed, ChatGPT even estimated that a fair Trump Media stock price might be as low as $5 if not lower – 45% below the press time price of $8.97 – it swiftly pivoted to explain that it remains a potentially lucrative sentiment play.
ChatGPT weighs in on DJT stock’s fundamentals-based price target. Source: Finbold & ChatGPT Specifically, OpenAI’s flagship product estimated that the downward momentum driving the equity since January 2 could exhaust itself later this summer, just as July 4 prompts President Trump to ‘re-enter the media cycle heavily’ with topics less grim than the dominant narratives of early 2026.
Lastly, the AI estimated that, between the holiday and the 2025 summer DJT stock rally, retail investors might move into position for a short-term play centered on the highly symbolic date.
Therefore, ChatGPT settled for a surprisingly optimistic possible July 4, 2026, price target for Trump Media shares: $11.40, implying a 27.09% rally from the May 29, press time price of $8.97.
ChatGPT sets DJT stock price target for July 4, 2026. Source: Finbold & ChatGPT Unprompted, the large language model (LLM) also offered a quote to summarize its thesis:
ChatGPT expects DJT to rebound to $11.40 by July 4, 2026, not because the fundamentals improved dramatically, but because Trump Media increasingly trades as a political-meme-crypto sentiment vehicle rather than a conventional media stock.
Lastly, it is worth noting that ChatGPT emphasized that, while it sees a July 4 Trump Media stock rally as plausible, it does not foresee it as altering the company fundamentals, nor leading to reliably elevated prices.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Trump Media & Tech shares are powering higher. Why are DJT shares rallying? The underlying business remains under pressure. DJT reported revenue of $871,200 with a gross margin of -72.3%. The company posted a net loss of $405.8 million and an EPS of -$1.47. Revenue growth sits at only 1.76% year over year, which shows how slowly the business is expanding.
What The Charts SayThe technical picture is still structurally challenged. DJT is trading 28.2% below its 200-day SMA at $12.55 and 12.7% below its 100-day SMA at $10.32, confirming the stock remains in a longer-term downtrend. Even with Thursday’s strength, DJT is still fractionally below its 50-day SMA at $9.10, keeping the intermediate trend under pressure.
RSI sits at 46.62, a neutral reading that points to choppy range-bound trading rather than a momentum-driven breakout or a washed-out capitulation low. The moving average stack stays unfavorable with the 20-day SMA below the 50-day and the 50-day below the 200-day, a bearish alignment that has historically seen rallies sold into resistance.
The one constructive near-term detail is that price has reclaimed both the 20-day SMA at $8.68 and the 20-day EMA at $8.81. Holding above those levels is the minimum condition for bulls to argue for any follow-through.
Key Level to Watch:
$8 is the nearby support zone where buyers have previously stepped in, sitting just above the 52-week low of $7.86. A break below that level would likely invite fresh selling pressure. Benzinga Edge SnapshotDJT’s momentum is flagged Bearish with a score of 3.55, signaling very weak trend strength versus the broader market. Rallies remain prone to fading until the stock can first build a base above $8 and then mount a sustained reclaim of the 50-day moving average. Until that happens the trend profile stays under pressure and the burden of proof remains on the bulls.
DJT Shares Are Trending HigherDJT Price Action: Trump Media shares were up 4.40% at $9.01 at the time of publication on Thursday. The stock is near its 52-week low of $7.86, according to Benzinga Pro.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
SARASOTA, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (Nasdaq: DJT) (“TMTG”) and TAE Technologies, Inc. (“TAE”) today announced that they remain focused on completing their previously-announced merger (the “TAE Merger”) as soon as possible, with the goal of closing the transaction in the fourth quarter of 2026 or sooner.
Trump Media and Technology and TAE Technologies said on Wednesday they have decided to not spin off Truth Social and certain other TMTG media assets into a new publicly listed company.
ToplinePresident Donald Trump’s media company has abandoned plans to spin off the Truth Social platform as a separate, publicly traded business, the company announced on Wednesday, as it plans to complete a $6 billion merger with TAE Technologies “as soon as possible.”
A merger between Trump Media and a fusion energy firm is expected “as soon as possible.”
Getty Images
Key FactsTrump Media & Technology Group, the fusion firm TAE Technologies and the special-purpose acquisition company Texas Ventures III disclosed they would no longer pursue a spin-off of Truth Social or other Trump Media assets “after further evaluation,” though they did not provide a reason for abandoning the idea.
Truth Social would have merged with Texas Ventures III after Trump Media merged with TAE Technologies, after which shares of the spun-off company would have been distributed to shareholders before the transaction closed, the companies announced in February.
Trump Media and TAE Technologies said they plan to close their merger “as soon as possible,” with a goal of closing by Q4 2026 “or sooner.”
Shares of Trump Media dropped slightly (0.3%) shortly after trading opened on Wednesday, extending losses for the stock that has plunged by nearly 41% so far this year.
big number$2.2 billion. That’s Trump Media’s market value as of Wednesday, a nearly 75% slide from its all-time high of roughly $8.7 billion in January 2025.
forbes valuationTrump has a net worth of $6.1 billion, ranking the president as the 665th-richest person in the world, according to Forbes’ estimates. He holds a 52% stake in Trump Media, totaling some 114.7 million shares worth about $932.5 million as of Wednesday’s share price.
key backgroundTrump Media and TAE Technologies announced in December they would merge in a deal valued at $6 billion, after which the Truth Social parent said it would build the “world’s first utility-scale fusion power plant” that could generate 50 megawatts of electricity. The Trump-owned firm went public in March 2024 through a reverse merger with Digital World Acquisition Corp., and trading in the stock has been frequently volatile. Trump Media has expanded to cryptocurrency, announcing last year it would launch Truth.Fi, a financial services brand, with other plans to enter the prediction markets business. Those plans included allowing users to bet on events like political elections and inflation-rate changes in a partnership with Crypto.com.
further readingForbesTrump’s Truth Social Could Become Its Own Company As Parent Firm Floats Spin-OffBy Ty Roush
@Stockstotrade's Tim Bohen offers his Big 3 picks he sees as formidable in the current volatile trading environment. He points to further rallies in Smith & Wesson Brands (SWBI) as the U.S.-Iran War continues, Apple (AAPL) as a stronghold in AI and tech, and Dell Technologies (DELL) as a "go to" for data center expansion.
Maryville, Tennessee--(Newsfile Corp. - June 3, 2026) - Smith & Wesson Brands, Inc. (NASDAQ Global Select: SWBI), a U.S.-based leader in firearm manufacturing and design, today announced it plans to release its fourth quarter and full fiscal 2026 financial results on Wednesday, June 17, 2026, after the close of the market. The full text of the press release will be available on the Smith & Wesson Brands, Inc. web site at www.smith-wesson.com under the Investor Relations section.
The company will host a conference call and webcast on June 17, 2026 to discuss its fourth quarter and full fiscal 2026 financial and operational results. Speakers on the conference call will include Mark Smith, President and Chief Executive Officer, and Deana McPherson, Executive Vice President and Chief Financial Officer. The conference call may include forward-looking statements. The conference call and webcast will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Interested parties in North America are invited to participate by dialing 1-877-704-4453. Interested parties from outside North America are invited to participate by dialing 1-201-389-0920. Participants should dial in at least 10 minutes prior to the start of the call. A live and archived webcast of the event will be available on the company's website at www.smith-wesson.com under the Investor Relations section.
About Smith & Wesson Brands, Inc.
Smith & Wesson Brands, Inc. (NASDAQ Global Select: SWBI) is a U.S.-based leader in firearm manufacturing and design, delivering a broad portfolio of quality handgun, long gun, and suppressor products to the global consumer and professional markets under the iconic Smith & Wesson® and Gemtech® brands. Additionally, the company provides manufacturing services such as forging and machining to third parties and offers world-class firearm training programs to Law Enforcement/Military departments and civilians at the Smith & Wesson Academy™ in Maryville, TN. For more information call (844) 363-5386 or visit www.smith-wesson.com.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299815
Smith & Wesson offers strong growth and a growing dividend, which appeals to both income and yield investors. Handguns remain SWBI's core, comprising nearly 80% of sales and driving a favorable product mix that boosted gross margin to 26.2%. Recent Google Search Trends reveal that interest has remained at a recent high in 2026 for Smith & Wesson products.
Atlanta, GA., March 12, 2026 (GLOBE NEWSWIRE) -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace for firearms, hunting and related products, has announced that it will participate in the 38th Annual ROTH Conference from March 22-24th, 2026 in Dana Point, CA
This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from hundreds of private and public companies in a variety of growth sectors including: Business Services, Consumer, Healthcare, Industrial Growth, Insurance, Resources, Sustainability and Technology, Media & Entertainment. As always, attendees with receive the true ROTH experience with many social components including networking, entertainment and athletic charity events. To learn more and submit a registration request, visit https://ibn.fm/Roth2026Registration
With many of the Company’s legacy legal matters now substantially resolved, management intends to place renewed emphasis on proactive investor engagement and market visibility. The Company plans to participate in additional investor conferences, expand its investor relations initiatives, and foster a more dynamic and transparent dialogue with the investment community. Management believes these efforts will help highlight the Company’s strategic positioning, operational momentum, and long-term growth opportunities while strengthening relationships with both current and prospective investors.
About Outdoor Holding Company
Outdoor Holding Company is the publicly traded parent and operator of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting and related products. Third-party sellers list items on the site and federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed by using licensed firearms dealers as transfer agents. Launched in 1999, the GunBroker.com website is an informative, secure and safe way to buy and sell firearms, ammunition, shooting accessories and outdoor gear online. GunBroker promotes responsible ownership of firearms. For more information, visit: www.gunbroker.com.
About ROTH
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.
Statements contained in this press release that are not historical are considered “forward-looking statements” within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, among others, statements about the Company’s liquidity, capital resources, or ongoing operations, the business strategy, plans, objectives, expectations and intentions, and other statements that are not historical facts. Instead, they are based only on Company management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause actual results to differ materially from those described in forward-looking statements include, but are not limited to, the Company’s ability to maintain and expand its e-commerce business, the Company’s ability to introduce new features on its e-commerce platform that match consumer preferences, the Company’s ability to retain and grow its customer base, the impact of lawsuits, including securities class action lawsuits, stockholder derivative suits and enforcement actions by regulatory authorities, the impact of adverse economic market conditions, including from social and political factors, and the occurrence of any other event, change or other circumstances that could give rise to impacts on operating results. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on June 16, 2025, and additional disclosures the Company makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law, the Company expressly disclaims any obligation or undertaking to any updated forward-looking statements.
Contacts
For investors:
Darrow Associates
Phone: (917) 886-9071 [email protected]
Outdoor (NASDAQ:POWW – Get Free Report) and Saab (OTCMKTS:SAABY – Get Free Report) are both aerospace companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Analyst Ratings This is a summary of current ratings and recommmendations for Outdoor and Saab, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outdoor 1 1 2 0 2.25 Saab 2 1 0 0 1.33 Outdoor presently has a consensus target price of $2.40, suggesting a potential upside of 15.94%. Given Outdoor’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Outdoor is more favorable than Saab.
Profitability This table compares Outdoor and Saab’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Outdoor -161.16% -8.65% -7.16% Saab 7.99% 15.73% 5.82% Risk & Volatility Outdoor has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Saab has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
Valuation and Earnings This table compares Outdoor and Saab”s revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Outdoor $49.40 million 4.91 -$130.83 million $0.04 51.75 Saab $8.42 billion 4.38 $645.29 million $0.74 46.53 Saab has higher revenue and earnings than Outdoor. Saab is trading at a lower price-to-earnings ratio than Outdoor, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership 26.4% of Outdoor shares are held by institutional investors. 25.0% of Outdoor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary Outdoor beats Saab on 8 of the 14 factors compared between the two stocks.
About Outdoor (Get Free Report)
AMMO, Inc. designs, produces, and markets ammunition and ammunition component products for sport and recreational shooters, hunters, individuals seeking home or personal protection, manufacturers, and law enforcement and military agencies. The company's products include STREAK Visual Ammunition that enables shooters to see the path of the bullets fired by them; and Stelth Subsonic ammunition primarily for suppressed firearms. It also owns and operates GunBroker.com, an auction site that supports the lawful sale of firearms, ammunition, and hunting/shooting accessories. In addition, the company's products comprises of armor piercing and hard armor piercing incendiary precision ammunition; and ammunition casings for pistol ammunition through large rifle ammunition. The company has a license agreement with Jeff Rann's ammunition for game hunting. AMMO, Inc. was founded in 2016 and is based in Scottsdale, Arizona.
About Saab (Get Free Report)
Saab AB (publ) provides products, services, and solutions for military defense, aviation, and civil security markets worldwide. The company operates through Aeronautics, Dynamics, Surveillance, Kockums, and Combitech segments. The company develops military aviation technology, as well as conducts studies on manned and unmanned aircraft. It also provides ground combat weapons, missile systems, torpedoes, unmanned underwater vehicles, training and simulation systems, and signature management systems for armed forces; and niche products for the civil and defense market, such as underwater vehicles for the offshore industry. In addition, the company offers solutions for safety and security, surveillance and decision support, and threat detection, location, and protection, including airborne, ground-based and naval radar, electronic warfare, and combat systems, as well as C4I solutions. Additionally, it provides submarines with the Stirling system for air independent propulsion, surface combatants, mine hunting systems, and autonomous vessels; and systems development, systems integration, information security, systems security, communications, mechanics, and technical product information and logistics. Saab AB (publ) was incorporated in 1937 and is headquartered in Stockholm, Sweden.
Receive News & Ratings for Outdoor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outdoor and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGreif, Inc. (NYSE:GEF) Given Average Rating of “Hold” by Analysts
NEXT HEADLINE »OPAL Fuels Inc. (NASDAQ:OPAL) Receives Average Rating of “Reduce” from Brokerages
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Outdoor Holding Company (POWW - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Outdoor Holding Company currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if POWW is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For POWW, shares are up 10.11% over the past week while the Zacks Aerospace - Defense Equipment industry is up 3.51% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 1.98% compares favorably with the industry's 1.32% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Outdoor Holding Company have increased 12.57% over the past quarter, and have gained 60.94% in the last year. On the other hand, the S&P 500 has only moved -1.76% and 26.51%, respectively.
Investors should also take note of POWW's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now POWW is averaging 569,071 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with POWW.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost POWW's consensus estimate, increasing from -$0.11 to -$0.07 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that POWW is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Outdoor Holding Company on your short list.
Atlanta, GA, May 18, 2026 (GLOBE NEWSWIRE) -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“Outdoor Holding Company,” “OHC,” or the “Company”) the owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports industries, and a leading vertically integrated producer of high-performance ammunition and components, today announced that the holders of record of the Company’s 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) as of the close of business on June 1, 2026 will receive a cash dividend equal to $0.546875 per Series A Preferred Stock share. The cash dividend will be paid on June 15, 2026.
About Outdoor Holding Company.
With its corporate offices headquartered in Atlanta, Georgia, Outdoor Holding Company is a publicly traded corporation that owns and operates subsidiaries serving outdoor enthusiasts, including GunBroker.com
About GunBroker.com
GunBroker.com is the largest online marketplace dedicated to firearms, hunting, shooting and related products. Aside from merchandise bearing its logo, GunBroker.com currently sells none of the items listed on its website. Third-party sellers list items on the site and Federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed using licensed firearms dealers as transfer agents. Launched in 1999, GunBroker.com is an informative, secure and safe way to buy and sell firearms, ammunition, air guns, archery equipment, knives and swords, firearms accessories and hunting/shooting gear online. GunBroker.com promotes responsible ownership of guns and firearms. For more information, please visit: www.gunbroker.com.
Forward Looking Statements
This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.
Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports filed on Form 8-K.
Atlanta, GA., June 01, 2026 (GLOBE NEWSWIRE) -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace for firearms, hunting and related products, today announced the appointment of Erich Buerger as Director of AI Strategy & Implementation. In this newly created role, Mr. Buerger will lead the development, coordination, and execution of artificial intelligence initiatives across the Company.
The appointment reflects OHC’s commitment to deploying artificial intelligence in disciplined, high-value ways that enhance marketplace functionality, operational efficiency, and long-term shareholder value. Mr. Buerger will be responsible for developing and executing the Company’s AI strategy in alignment with corporate objectives, identifying high-value AI use cases across departments, establishing AI governance frameworks and responsible-use policies, and overseeing the evaluation, selection, and deployment of AI tools, platforms, and vendors throughout the organization.
A Proven AI Veteran and Digital Transformation Leader
Mr. Buerger brings more than 20 years of experience translating emerging technologies into measurable business outcomes, with a track record of identifying high-impact AI opportunities, leading cross-functional implementation, and integrating solutions into core business workflows. He joins OHC from Ecommerce LabWorks, where he served as Head of eCommerce Artificial Intelligence, leading AI strategy and the deployment of systems built on large language models, natural language processing, and agentic workflows.
“Erich brings exactly the combination of strategic vision and hands-on implementation experience we need to scale our AI capabilities responsibly and profitably,” said Steve Urvan, Chief Executive Officer of OHC. “We view disciplined AI deployment as a long-term value creation strategy for shareholders. Establishing dedicated leadership for our AI strategy is a natural next step in that commitment, and we are confident Erich will help us unlock meaningful operating leverage across the business.”
“OHC sits at the intersection of a category-leading marketplace and nearly three decades of proprietary data, which is a rare foundation for building AI that delivers real, measurable impact,” said Mr. Buerger. “I’m excited to partner with the leadership team to identify the highest-value opportunities and turn them into solutions that improve efficiency, automation, and decision-making across the organization.”
Advancing the Company’s AI Roadmap
The appointment builds on OHC’s broader technology roadmap, including the recent launch of its proprietary AI-powered listing tool on the GunBroker marketplace. Under Mr. Buerger’s leadership, the Company will continue to evaluate and implement responsible AI-driven enhancements aimed at improving user experience, optimizing marketplace performance, and unlocking additional operating leverage across its platform.
About Outdoor Holding Company
Outdoor Holding Company is the publicly traded parent and operator of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting and related products. Third-party sellers list items on the site and federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed by using licensed firearms dealers as transfer agents. Launched in 1999, the GunBroker.com website is an informative, secure and safe way to buy and sell firearms, ammunition, shooting accessories and outdoor gear online. GunBroker promotes responsible ownership of firearms. For more information, visit: www.gunbroker.com.
Statements contained in this press release that are not historical are considered “forward-looking statements” within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, among others, statements about the Company’s liquidity, capital resources, or ongoing operations, the business strategy, plans, objectives, expectations and intentions, and other statements that are not historical facts. Instead, they are based only on Company management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause actual results to differ materially from those described in forward-looking statements include, but are not limited to, the Company’s ability to maintain and expand its e-commerce business, the Company’s ability to introduce new features on its e-commerce platform that match consumer preferences, the Company’s ability to retain and grow its customer base, the impact of lawsuits, including securities class action lawsuits, stockholder derivative suits and enforcement actions by regulatory authorities, the impact of adverse economic market conditions, including from social and political factors, and the occurrence of any other event, change or other circumstances that could give rise to impacts on operating results. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on June 16, 2025, and additional disclosures the Company makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law, the Company expressly disclaims any obligation or undertaking to any updated forward-looking statements.
Contacts
For investors:
Darrow Associates
Phone: (917) 886-9071 [email protected]
Atlanta, Georgia, June 08, 2026 (GLOBE NEWSWIRE) -- Outdoor Holding Company (NASDAQ: POWW/POWWP) (“Outdoors Online,” “we,” “us.” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace for firearms, hunting and related products, announced that it will release financial results for its fourth quarter of its 2026 fiscal year premarket on June 22, 2026.
Management will host a conference call at 9:00 AM ET on June 22, 2026 to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
The conference call will primarily be available through a live webcast at the following link: https://events.q4inc.com/attendee/339194298, which is also available through the Company’s website. The recording of the webcast will be posted on the Company’s website after the call is completed.
Those without internet access may dial in by calling (855) 761-5600 (domestic) or 1(646) 307-1097 (international). Please join at least 5-10 minutes prior to the scheduled start and follow the operator’s instructions. When requested, please ask for the “Outdoor Holding Company Conference Call” or reference Conference ID #: 2981188.
About Outdoor Holding Company
With its corporate offices now headquartered in Atlanta, Georgia, Outdoor Holding Company is a publicly traded corporation that owns and operates subsidiaries serving outdoor enthusiasts, including GunBroker.
About GunBroker
GunBroker.com is the largest online marketplace dedicated to firearms, hunting, shooting and related products. Aside from merchandise bearing its logo, GunBroker currently sells none of the items listed on its website. Third-party sellers list items on the site and Federal and state laws govern the sale of firearms and other restricted items. Ownership policies and regulations are followed using licensed firearms dealers as transfer agents. Launched in 1999, the GunBroker.com site is an informative, secure and safe way to buy and sell firearms, ammunition, air guns, archery equipment, knives and swords, firearms accessories and hunting/shooting gear online. GunBroker promotes responsible ownership of firearms. For more information, please visit: www.gunbroker.com.
Forward-Looking Statements
This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.
Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports filed on Form 8-K.
, /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company.
The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 50,625 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."
All of the above-described Awards were granted outside of the Company's stockholder-approved equity incentive plans pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the "Board") in April 2026. The Awards were approved by the Board's Human Capital Management Committee, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart overcoming challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 and ATR 1086, and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
, /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.
"This milestone marks a meaningful step forward for Atrium, further expanding our RNA delivery platform and our ability to generate high quality cardiology development candidates," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "The successful advancement of this first development candidate reflects the strength of our science, the productivity of our collaboration with Bristol Myers Squibb, and our shared commitment to deliver transformative therapies for patients with cardiac disease."
The payment is pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications.
Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from the collaboration.
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.
For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
Availability of Other Information About Atrium Therapeutics
Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission ("SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Atrium Therapeutics posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About PRKAG2 Syndrome
PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells leading to thickened heart muscles, electrical conduction problems, and arrhythmias. There are 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.
About PLN Cardiomyopathy
PLN (phospholamban) cardiomyopathy is a rare autosomal dominant, progressive cardiac disease caused by mutations in PLN, a key regulator of SERCA2a calcium pump. PLN mutations produce protein aggregates that disrupt endoplasmic reticulum processes and lead to dilated, arrhythmogenic, or hypertrophic cardiomyopathies and a significantly increased risk of heart failure and sudden cardiac death. There are 2,000 – 4,000 people with pathogenic PLN variants in the US. No approved therapies target the underlying molecular cause of the disease.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ("Atrium's" or "our") future results of operations and financial condition; research and development plans; anticipated timing, design and conduct of ongoing and planned preclinical studies and clinical trials for product candidates; our expectations regarding our RNA delivery platform and ability to generate high quality cardiology development candidates, the timing and likelihood of regulatory filings and approvals for product candidates; the potential safety and therapeutic benefits of our product candidates; the timing and likelihood of success; plans and objectives of management for future operations; and future results of anticipated product development efforts. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our ability to maintain our current license agreements and collaborations and identify and enter into future license agreements and collaborations; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators in the future; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified in Atrium's Registration Statement on Form 10, initially publicly filed by Atrium with the Securities and Exchange Commission (the "SEC") on December 10, 2025 and in other filings and furnishings made by Atrium with the SEC from time to time. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.
, /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress following its launch as a public company.
"Our focused pipeline, strong cash balance and experienced team are driving significant momentum as we build a dedicated precision cardiology company," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "This quarter, we advanced our lead development programs, ATR 1072 and ATR 1086, while establishing the strategic and operational foundation required to pioneer RNA therapeutics in the precision cardiology space. With a clear strategy, a well-characterized RNA delivery platform and a deep commitment to patients, we believe we are well-positioned to advance therapies for people living with genetic cardiomyopathies who have limited or no therapeutic options."
Recent Highlights
Launched as an independent, publicly traded precision cardiology company. Atrium launched on February 27, 2026 following its separation and spin-off from Avidity Biosciences, Inc. (Avidity) after Novartis AG's acquisition of Avidity. Atrium began trading on the Nasdaq Global Select Market under the ticker symbol "RNA." Earned $15 million milestone payment from Bristol Myers Squibb (BMS). Atrium successfully delivered the first development candidate targeting a cardiology indication under its ongoing collaboration with BMS, triggering a $15 million milestone payment. Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Progressed ATR 1072 program toward the clinic. Atrium has conducted the Good Laboratory Practice (GLP) toxicology studies required for the submission of an Investigational New Drug (IND) application for ATR 1072, a potential treatment designed to address the underlying genetic cause of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Additionally, the Company has completed initial discussions with both the U.S. Food and Drug Administration (pre-IND meeting) and Health Canada (pre-CTA consultation meeting) regarding its proposed Phase 1/2 clinical trial design. Anticipated Upcoming Milestones
Submit IND application for ATR 1072 in the second half of 2026 Initiate Phase 1/2 clinical trial for ATR 1072, subject to regulatory clearance File IND application for ATR 1086 in 2027, with IND-enabling studies initiating in 2026 First Quarter 2026 Financial Results
Given the timing of Atrium's spin-off from Avidity, the operating results presented for the first quarter of 2026 are not necessarily indicative of the results for any future periods.
Collaboration Revenue: Collaboration revenue was $19.6 million for the first quarter of 2026, primarily related to the achievement of a $15 million development milestone pursuant to the Company's partnership with BMS, with the remainder related to R&D services. Research and Development (R&D) Expenses: R&D expenses were $16.7 million for the first quarter of 2026, primarily reflecting clinical trial preparations, IND-enabling activities, and continued development of the Company's overall research capabilities. General and Administrative (G&A) Expenses: G&A expenses were $20.3 million for the first quarter of 2026, driven by employee-related expenses, professional fees, and costs associated with launching Atrium as a publicly traded company. Cash and Cash Equivalents: As of March 31, 2026, Atrium had $267.8 million in cash and cash equivalents. The Company believes its current cash resources are sufficient to fund planned operations through key clinical proof-of-concept milestones. About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.
For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
Availability of Other Information About Atrium Therapeutics
Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission ("SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About PRKAG2 Syndrome
PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells leading to thickened heart muscles, electrical conduction problems, and arrhythmias. There are 1,000 – 2,000 people with PRKAG2 syndrome in the United States. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.
About PLN Cardiomyopathy
Phospholamban ("PLN") cardiomyopathy is a rare autosomal dominant, progressive cardiac disease caused by mutations in PLN, a key regulator of sarcoplasmic reticulum Ca2+-ATPase 2a ("SERCA2a") calcium pump. PLN mutations produce protein aggregates that disrupt endoplasmic reticulum processes and lead to dilated, arrhythmogenic, or hypertrophic cardiomyopathies and a significantly increased risk of heart failure and sudden cardiac death. There are 2,000 – 4,000 people with pathogenic PLN variants in the United States. No approved therapies target the underlying molecular cause of the disease.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ("Atrium's" or "our") future results of operations and financial condition; research and development plans; anticipated timing, design and conduct of ongoing and planned preclinical studies and clinical trials for product candidates; our expectations regarding our RNA delivery platform and ability to generate high-quality cardiology development candidates, the timing and likelihood of regulatory filings and approvals for product candidates; the potential safety and therapeutic benefits of our product candidates; the timing and likelihood of success; plans and objectives of management for future operations; and future results of anticipated product development efforts. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our ability to maintain our current license agreements and collaborations and identify and enter into future license agreements and collaborations; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators in the future; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified under the heading "Risk Factors" in Atrium's Registration Statement on Form 10-12B/A, as amended (File No. 001-43008), which was filed with the SEC and became effective on February 26, 2026, most recent Quarterly Report on Form 10-Q filed with the SEC and in other filings and furnishings made by Atrium with the SEC from time to time, which are all available on the SEC's website at www.sec.gov. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.
Atrium Therapeutics, Inc.
Selected Condensed Financial Information
(in thousands except share and per share information)
(Unaudited)
Statements of Operations
Three Months Ended March 31,
2026
2025
Collaboration revenue
$
19,635
$
1,573
Operating expenses:
Research and development
16,657
6,937
General and administrative
20,258
2,088
Total operating expenses
36,915
9,025
Loss from operations
(17,280)
(7,452)
Other income, net
647
3
Net loss and comprehensive loss
$
(16,633)
$
(7,449)
Basic and diluted net loss per common share
$
(0.97)
$
(0.44)
Weighted average common shares outstanding used in the calculation of basic and diluted
net loss per common share
17,105,643
17,105,643
Balance Sheets
March 31,
December 31,
2026
2025
Assets
Current assets:
Cash and cash equivalents
$
267,849
$
—
Collaboration receivable
15,000
—
Prepaid assets
2,578
1,535
Other current assets
138
1,310
Total current assets
285,565
2,845
Restricted cash
415
—
Property and equipment, net
4,337
2,724
Right-of-use asset
2,043
2,784
Total assets
$
292,360
$
8,353
Liabilities and Stockholders' Equity/Former Parent Deficit
Current liabilities:
Accounts payable
$
807
$
4,398
Accrued liabilities
6,983
8,945
Accrued compensation
2,091
3,147
Lease liabilities
2,680
3,672
Deferred revenue, current portion
9,344
21,639
Total current liabilities
21,905
41,801
Deferred revenue, net of current portion
36,351
28,691
Other long-term liabilities
—
574
Total liabilities
58,256
71,066
Commitments and contingencies
Stockholders' equity/ Former Parent's deficit:
Preferred stock, $0.001 par value: 40,000,000 shares authorized; no shares issued and
outstanding
—
—
Common stock, $0.001 par value: 400,000,000 shares authorized; 17,105,643 shares
issued and outstanding as of March 31, 2026, and no shares authorized, issued, or
outstanding as of December 31, 2025
16
—
Additional paid-in capital
221,960
—
Retained earnings
12,128
—
Net Investment from Former Parent
—
(62,713)
Total stockholders' equity/Former Parent's deficit
234,104
(62,713)
Total liabilities and Stockholders' equity/Former Parent's deficit
March 25, 2026 16:15 ET | Source: Emergent BioSolutions
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6 million USD. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent’s medical countermeasures portfolio and will support the partner’s smallpox biodefense strategy. These orders stem from a recurring international customer and demonstrate the importance of threat preparedness around the world.
“We are pleased to support both the U.S. government and a longstanding international partner with critical smallpox medical countermeasures that directly align with their national security and public health preparedness efforts,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Our strong track record of developing, manufacturing and supplying biodefense products to international governments reinforces the strength of our partnerships, particularly in light of the growing risk of biological threats globally.”
This announcement follows Emergent’s recent execution of multi-year agreements with the Government of Canada valued up to $140 million CAD to support the country’s biologic threat preparedness and response infrastructure, of which, more than $35 million CAD orders will be received in 2026.
U.S. FDA-Approved Indication and Select Important Safety Information for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV)
Indication
VIGIV is an Immune Globulin (Human), 5% Liquid, indicated for the treatment of complications due to vaccinia vaccination including eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, vaccinia infections in individuals who have skin conditions, and aberrant infections induced by vaccinia virus (except in cases of isolated keratitis). VIGIV is not indicated for postvaccinial encephalitis.
Important Safety Information
Warning
: Interactions with Glucose Monitoring SystemsBlood glucose measurement in patients receiving Vaccinia Immune Globulin Intravenous (Human) (VIGIV) must be done with a glucose-specific method (monitor and test strips) to avoid interference by maltose contained in VIGIV. Maltose in IGIV products may give falsely high blood glucose levels in certain types of blood glucose testing systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. Cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings.
Contraindications: VIGIV is contraindicated in isolated vaccinia keratitis, individuals with a history of anaphylactic or severe systemic reaction to human globulins, and IgA-deficient patients with antibodies against IgA and a history of IgA hypersensitivity.
Warnings & Precautions:
Hypersensitivity to human immune globulin (acute anaphylaxis)Acute renal dysfunction/failureThrombosis may occur with immune globulin products, including VIGIV. For patients at risk of thrombosis, administer VIGIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosityHemolysis or hemolytic anemiaAseptic meningitis syndrome (AMS)Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)]Transmission of infectious agents from human plasmaMonitor renal function and urine output in patients at risk of renal failure; check baseline blood viscosity in patients at risk of hyperviscosity; and conduct confirmatory tests if hemolysis or TRALI is suspected Adverse Reactions: The adverse drug reactions to VIGIV treatment in clinical trials (>10%) include headache, nausea, rigors and dizziness.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or [email protected]; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information for VIGIV for complete Boxed Warning and safety information.
U.S. FDA-Approved Indication and Select Important Safety Information for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Indication
ACAM2000® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.
Important Safety Information
Warning: Serious Complications
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000® or other live vaccinia virus vaccines that were used historically. These risks are increased in certain individuals and may result in severe disability, permanent neurological sequelae and/or death.
Contraindications: Do not administer ACAM2000® to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.
Warnings & Precautions: Myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal vaccinia, fetal death, and accidental eye infection (ocular vaccinia) that may lead to blindness.
Adverse Reactions: Inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or [email protected]; or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.
Please see the full Prescribing Information for ACAM2000® for complete Boxed Warning and safety information.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the availability and government procurement of CNJ-016® and ACAM2000® are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences:
London Defence Conference, April 10-11, London, United KingdomCBRN Research & Innovation Conference, May 19-21, Arcachon, FranceGlobal Health Security Conference, June 9-12, Kuala Lumpur, MalaysiaBIO International Convention, June 20-22, San Diego, California, United States “As the world navigates an increasingly complex health threat landscape, Emergent is committed to working with governments to help protect regional and global security,” said Paul Williams, senior vice president, head of products business, global government and public affairs. “We look forward to engaging with government and industry leaders to discuss how together we can strengthen preparedness and help protect and save lives.”
Emergent specializes in developing, manufacturing and delivering medical countermeasures to governments around the world for security and preparedness. These products support emergency response preparedness and help protect the public from critical threats like smallpox, anthrax, botulism and Ebola. Learn more about how we help protect people worldwide from biological threats at emergentbiosolutions.com/biothreats.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO [email protected]
Media Contact:
Assal Hellmer
Vice President, Communications [email protected]
GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the public to be ready to respond to an opioid overdose. These include the launch of the new NARCAN® Nasal Spray Carrying Case, the expanded availability of NARCAN® Nasal Spray multipacks and a college campus engagement featuring Pro Football Hall of Famer, Emmitt Smith and Release Recovery Founder/CEO, Zac Clark at Southern Methodist University (SMU).
The new NARCAN® Nasal Spray Carrying Case is designed to be easy to carry, compact, discreet and durable, helping to ensure it's on hand when needed most. Additionally, Emergent is expanding the availability of NARCAN® Nasal Spray multipacks to include 6-count and 24-count options, specifically designed to meet the needs of partners distributing higher volumes of naloxone.
"The opioid epidemic continues to impact individuals and communities every day, and each tool we can provide to increase preparedness and reduce stigma is vital," said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "The availability of the NARCAN® Nasal Spray Carrying Case and multipack options underscores our commitment to making naloxone as accessible as possible. Coupled with our campus outreach, we are working to empower more people to respond in an opioid emergency."
In line with these expanded access efforts, Emergent's Ready to Rescue campaign will visit SMU with campaign spokespeople Emmitt Smith and Zac Clark to host a conversation with students focused on mental health, dismantling the stigma associated with accidental opioid overdose and the importance of carrying NARCAN® Nasal Spray.
Research indicates a significant need for increased preparedness, with a recent survey finding that only one in 10 of the general population currently carries naloxone.1 Among college students, a high-risk group, 81 percent expressed a preference for a case to carry NARCAN® Nasal Spray.2 The new carrying case, designed to clip easily onto backpacks or bags, addresses this need, making it a seamless part of daily life.
"The reality is that opioid overdose emergencies can happen anytime, anywhere and to anyone," said Emmitt Smith. "That's why I’m passionate about encouraging everyone – especially college students – to be prepared. Being ready to rescue means carrying NARCAN® Nasal Spray and knowing how to use it, because you never know when you could help save someone’s life."
Opioid misuse and dependency are highest among young adults ages 18 to 25,3 and about one in three college students know someone who has overdosed.4 With young adults having an increased risk of witnessing or experiencing an opioid emergency, building preparedness on college campuses has never been more important. To this end, Emergent is engaging with hundreds of college/university leaders across the country to increase awareness of the new carrying case and encourage life-saving efforts on their campuses.
"Every minute counts in an opioid emergency and having NARCAN® Nasal Spray readily available can be the difference between life and death," said Dr. Bonnie Milas, Clinical Professor of Anesthesiology and Critical Care Medicine at the University of Pennsylvania. "The new carrying case makes it simple to keep this life-saving medication with you, just like you would a first-aid kit, and with the multipacks, business and community organizations can ensure they have enough doses to be prepared."
The NARCAN® Nasal Spray Carrying Case is now available on Amazon. The NARCAN® Nasal Spray Multipacks are available on NarcanDirect.com for public interest customers. For more information, visit NARCAN.com.
Emmitt Smith and Zac Clark are paid spokespeople for Emergent BioSolutions.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO [email protected]
Media Contact:
Assal Hellmer
Vice President, Communications [email protected]
1 https://doi.org/10.1001/jamanetworkopen.2024.62698
2 Emergent BioSolutions. Consumer Research for NARCAN® Nasal Spray Carrying Case (509 adults online in Q3 2025). Data on file.
3 https://doi.org/10.3390/ijerph19010022
4 https://www.ue.org/risk-management/health-and-well-being/respond-to-student-opioid-overdoses
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3fcbfc65-93d7-475f-9f23-b47fbf2ab8ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/2c07f51b-ca7f-456d-b090-34479583785e
https://www.globenewswire.com/NewsRoom/AttachmentNg/5162a7ae-5927-4115-a849-83c1dad70ffd
WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program). This order follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s nasal naloxone pilot program, which launched in 2024, and provided 60,000 nasal naloxone kits to community sites, pharmacies, post-secondary institutions, First-Nations-mandated institutions, fire departments, municipalities and libraries.
“We applaud the B.C. Ministry of Health for their efforts to make nasal naloxone available to communities across B.C. and empower more people to be ready to save a life in the event of an opioid poisoning,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “We are proud to deliver products to help protect and save lives through our footprint in Canada with over 300 employees across Emergent’s Winnipeg, Manitoba manufacturing facility and offices in Mississauga, Ontario.”
Emergent has longstanding partnerships with the Government of Canada and several provincial and territorial governments to deliver products that protect against public health threats. Since 2016, Emergent has delivered more than 100 million doses of NARCAN® Nasal Spray to people, communities and businesses across Canada and the U.S. to help save lives from opioid poisonings. NARCAN® Nasal Spray is designed to reverse the effects of an opioid poisoning within minutes and is part of Emergent’s opioid response program to equip the government, community organizations, pharmacies, workplaces and care providers with a suite of tools to help manage the crisis.
“This initial order is an important milestone in our commitment to increasing access and awareness of NARCAN® Nasal Spray to help address the opioid poisoning crisis across Canada,” said Danielle Portnik, country manager and head of business Canada at Emergent. “We are partnering closely with the BCCDC, Ministry of Health, and the Provincial and Regional Health Authorities on these efforts as NARCAN® Nasal Spray is rolled out across the province beginning this month.”
NARCAN® Nasal Spray can be accessed at no cost to all residents of Ontario, Quebec, Nova Scotia, Northwest Territories, Nunavut and the Yukon, through the provincial and territorial THN (or equivalent) programs. It is also available through Veteran Affairs Canada, First Nations Health Authority (FNHA) and Non-Insured Health Benefits (NIHB) program. NARCAN® Nasal Spray can also be ordered online at www.OrderNARCAN.ca.
Learn more about Emergent’s commitment to help combat the opioid crisis in Canada via this National Impact Map.
About NARCAN® Nasal Spray
NARCAN® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central nervous system depression.
While NARCAN® Nasal Spray can be administered by a non-health care professional, it is not intended to be a substitute for professional medical care. Always call 911 as soon as an opioid overdose is suspected, before administering NARCAN® Nasal Spray.
Always read the label and follow the directions for use.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the B.C. government’s additional investment to expand the BC THN Program to include nasal naloxone, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO [email protected]
Media Contact:
Assal Hellmer
Vice President, Communications [email protected]
1Province of British Columbia. (2025) Statistical reports on deaths in British Columbia. Available at: https://www2.gov.bc.ca/gov/content/life-events/death/coroners-service/statistical-reports (Accessed: 23 February 2026).
2BC Pharmacy Association (2019) Review of naloxone delivery devices for bystander intervention. The Tablet, 15 October [online]. Available at: https://www.bcpharmacy.ca/tablet/fall-19/nasal-naloxone-delivery. (Accessed: 20 February 2026).
